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ABSTRACT 
 
 
Density Enhanced Phosphatase 1 (DEP-1) plays an important role in the regulation 
of cell growth, differentiation and transformation. DEP-1 was shown to be frequently 
lost in mammary, lung and colon tumors and in addition, the gene has been 
described as tumor suppressor gene. The protein is known for its antiproliferative 
effect due to the inhibition of MAP-Kinases. 
A knock-out mouse model demonstrated that DEP-1 is of fundamental importance for 
the vascular development. 
In the present study, we wanted to characterize a potential interaction partner that 
was identified before in my diploma thesis by a yeast-two-hybrid (Y2H) screen, 
Hepatitis B Core-Antigen Binding Protein (HBCBP). According to confocal 
microscopy data, the protein is a cytoplasmic protein. 
We could show that overexpression of full-length HBCBP significantly downregulated 
the activity of the ERK1/2 MAP-Kinase pathway in Elk-1 reporter assays, while 
truncated HBCBP did not. Furthermore, this inhibition could only be shown in dense 
cells, while in samples with sparse cells this activity was absent.  
Unfortunately we could not confirm the interaction between HBCBP and DEP-1 in the 
human system by co-immunoprecipitation. In addition, we found that the inhibition of 
the ERK1/2 MAP-Kinase pathway by HBCBP does not require the presence of DEP-
1 and that similarly the inhibition by DEP-1 does not require the presence of HBCBP.  
In western blots the amount of phosphorylated ERK1/2 was reduced in cells 
overexpressing HBCBP, though not in a statistically significant way. HBCBP did not 
interact with ERK1/2 directly and we could not find another interaction partner of 
HBCBP that medited the effect.  
To see, if HBCBP has a quantifiable effect on ERK1/2 MAP-Kinase dependent 
processes, we used proliferation and apoptosis studies showing that HBCBP had no 
influence. 
Searching for hints, in which processes HBCBP could be involved, we found the 
HBCBP expression to not be organ-specific, but detected an upregulation of HBCBP 
expression upon TGFβ1 and IFNγ treatment in HUVECs, though not significant. 
We used different software programs to analyze the protein sequence of HBCBP to 
get information about conserved domain patterns, evolutionaly relationships, 
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homologous regions and phosphorylation sites, but none of these approaches could 
give us promising results. Interestingly a ClustalW2 analysis indicated an HBCBP-
orthologue in chimpanzee, but there are no related genes in human. 
Also our last attempt to express and purify recombinant HBCBP for later antibody 
production was confronted with severe limiting difficulties.  
Taken together, we found that HBCBP does not interact with DEP-1 in a detectable 
way. Although we found an inhibition of the ERK1/2 pathway in reporter assays by 
HBCPB that were confirmed by siRNA analyses, this signaling pathway did not 
involve apoptosis or proliferation, leaving the option that HBCBP influences other 
ERK1/2 dependent processes.  
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ZUSAMMENFASSUNG 
 
 
Density Enhanced Phosphatase 1 (DEP-1) spielt eine wichtige Rolle in der 
Regulation von Zellwachstum, Differenzierung und Transformation. Es wurde 
gezeigt, dass DEP-1 in verschiedenen humanen Tumoren mutiert ist. DEP-1 wurde 
zusätzlich als Tumorsuppressor-Gen beschrieben. Das Protein inhibiert MAP-
Kinasen und hat daher einen antiproliferativen Effekt. 
In Knock-out-Mäusen konnte gezeigt werden, dass die Anwesenheit von DEP-1 von 
fundamentaler Wichtigkeit für die Entwicklung des Gefäßsystems ist. 
In dieser Studie wollten wir einen potentiellen Interaktionspartner von DEP-1 
charakterisieren, der zuvor durch einen Yeast-Two-Hybrid (Y2H) screen identifiziert 
worden ist, Hepatitis B Core-Antigen Binding Protein (HBCBP). Konfokale 
Mikroskopie zeigte, dass HBCBP ein cytoplasmatisch lokalisiertes Protein ist. 
Wir konnten zeigen, dass Überexpression von HBCBP, aber nicht von gekürzten 
HBCBP-Konstrukten, die Aktivität des ERK1/2 MAP-Kinase-Signalweges in Elk-1 
Reporterassays signifikant gehemmt hat. Dies war auf die Inhibition in konfluenten 
Zellen beschränkt, während der Signalweg in subkonfluenten Zellen nicht gehemmt 
wurde.  
Im humanen System konnte eine Interaktion zwischen HBCBP und DEP-1 nicht 
durch Co-Immunoprezipitation bestätigt werden. Zusätzlich fanden wir, dass die 
Inhibierung des ERK1/2 MAP-Kinase-Signalweges durch HBCBP von DEP-1 
unabhängig war und dass ebenfalls die Inhibierung durch DEP-1 von HBCBP 
unabhängig war. 
In Western-Bots war in HBCBP-überexprimierenden Zellen die Menge von 
phosphoryliertem ERK1/2 reduziert, jedoch nicht statistisch signifikant. HBCBP 
interagierte nicht direkt mit ERK1/2 und wir konnten auch keinen Interaktionspartner 
von HBCBP finden, der diesen Effekt vermittelte. Proliferations- und Apoptosestudien 
zeigten, dass HBCBP darauf keinen Einfluss hatte.  
Die Expression von HBCBP war nicht organspezifisch, aber konnte eine 
Hochregulierung der HBCBP-Expression in HUVECs durch TGFβ1 und IFNγ 
festgestellt werden, jedoch nicht in einem signifikanten Ausmaß. 
Wir benutzten unterschiedliche Softwareprogramme für die Analyse der 
Proteinsequenz von HBCBP, um Information über konservierte Domänen, 
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evolutionare Verwandtschaft, homologe Regionen und Phosphorylierungsstellen zu 
bekommen, aber , aber auch diese lieferten keine Hinweise auf die Funktion von 
HBCBP. Interessanterweise ließ eine ClustalW2-Analyse vermuten, dass HBCBP nur 
im Chimpansen wiederzufinden ist, es gibt keine eng verwandten Gene im 
Menschen. 
Der Versuch, rekombinantes HBCBP für spätere Antikörperproduktion zu exprimieren 
und zu reiningen, wurde durch das ausschließliche Vorkommen in Inclusion-Bodies 
interkariert.  
Zusammenfassend haben wir gefunden, dass HBCBP mit DEP-1 nicht in einem 
detektierbarem Ausmass interagierte. Obwohl wir eine Inhibierung des ERK1/2-
Signalweges durch HBCBP in Reporterassays fanden, was durch si-RNA-Analysen 
bestätigt wurden, konnten wir keine Auswirkungen auf Apoptose oder Proliferation 
feststellen, was die Möglichkeit offen lässt, dass HBCBP andere ERK1/2-abhängige 
Prozesse beeinflusst. 
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INTRODUCTION 
 
 
1. Cell cycle regulation 
 
 
Proliferation is the biological process of cell growth, in which two identical daughter 
cells are generated by cell division of a single progenitor cell. Different types of cells 
have very different rates of proliferation. For example, cells of the skin are vividly 
dividing, whereas liver cells only divide in case of injury to recover the damaged 
tissue. Certain specialized cells are entirely in growth arrest, like neurons or muscle 
cells. The rate of proliferation is tightly controlled by the cell cycle (Fig.A). 
In the cell cycle, the chromosome cycle can be distinguished from the growth cycle. 
The chromosome cycle includes DNA replication and the physical separation of the 
two complete genomes to daughter nuclei, while the growth cycle accounts for the 
replication of other cellular devices, like proteins, membranes, organelles, etc. and for 
the physical separation of the daughter cells. Accurate replication and partitioning is 
essential for the daughter cells to preserve the possibility of further cell divisions. The 
chromosome and growth cycles have to be strictly coordinated. Otherwise the cells 
would get gradually larger or smaller with each division (Tyson et al, 2002). 
The chromosome cycle of eukaryotic cells includes two basic processes. The DNA 
synthesis phase (S phase) is responsible for the replication of the DNA to produce 
identical pairs of sister chromatids. The mitosis phase (M phase) can be divided into 
prophase (chromosome condensation), metaphase (chromosome alignment at 
midplane of mitotic spindle), anaphase (separation of sister chromstids) and 
telophase (formation of daughter nuclei). The two phases are separated by two 
“gaps”, creating the generic cell cycle: G1-S-G2-M. Repeated S phases without M 
phases in between lead to the formation of large, polyploid cells which are generated 
in some cases of terminally differentiated cells (Tyson et al, 2002).  
To ensure a proper progression of the cell cycle checkpoints are controlling certain 
transitions. At the G1 checkpoint, the cell has to be large enough for DNA synthesis, 
any DNA damage has to be repaired and the external conditions have to be sufficient 
for mitosis before S phase is to be started. Cell division in multicellular organism 
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additionally underlie influences from growth hormones, cell-cell contacts and different 
other factors. The G2 checkpoint is responsible for the affirmation that the DNA was 
fully replicated, that damages were repaired and that the cell is large enough for 
division (Elledge et al, 1996). 
 
 
 
 
Figure A: Cell cycle. Cyclin-Cdk-complexes formed at the indicated points of the cell 
cycle.  
 
 
The main molecules regulating the cell cycle are enzymes called cyclin-dependent 
protein kinases (CDKs). CDKs are present in the cell throughout the cell cycle in a 
constant concentration. Their activity depends on the association with appropriate 
cyclins that vary in concentration during the different phases of cell cycle (Fig. A). 
The changing concentration of the different cyclins leads to the formation of certain 
cyclin-CDK-complexes at certain phases, determining the time frame of the different 
phases of the cell cycle. In that context, CDKs, by phosphorylation of target proteins, 
trigger major events like DNA replication, chromosome concentration and nuclear 
envelope breakdown (Tyson et al, 2002). 
Another important regulating factor for the cell cycle is the anaphase promoting 
complex (APC). It initiates degradation of the cyclin component of CDKs and causes 
G1
G0
SG2
Cyclin
D1,2,3
Cdk4,6
CyclinB,A
Cdc2
CyclinE
Cdk2
CyclinA
Cdk2
M
APC
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the separation of sister chromatids, and daughter cells are prepared for a new cell 
cycle. For a new round of cell cycle, the APC activity must then be turned off, so that 
CDK activity can accelerate (Novak et al, 1998). 
That indicates antagonistic interactions between CDK and APC. CDK inactivates 
APC and APC degrades the cyclin subunit of the CDK complex (Nasmyth, K., 1995). 
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2. Phosphorylation 
 
 
Phosphorylation is the key for basic processes in the cell. Complicated procedures, 
including gene regulation, cell cycle control, metabolic processes, motility, secretion, 
adhesion, proliferation and differentiation are synchronized by phosphorylation. 
Therefore the state of phosphorylation has to be under tight control. 
When a phosphate group binds to a protein, it causes a conformational change. 
Because of its two negative charges, the phosphate group could, for example, attract 
a cluster of positively charged amino acids. After the removal of the phosphate from 
the protein, it again takes over its former conformation. 
When a protein gets phosphorylated, a protein kinase transfers a phosphate group 
from adenosine triphosphate (ATP) to the hydroxyl group of a serine, threonine or a 
tyrosine amino acid side chain within the protein. Protein phosphatases can reverse 
this process (Fig. B). 
 
ProteinProtein
PATP ADP
Kinase
Pi
Phosphatase
 
 
Figure B: Scheme of the reversible phosphorylation of a protein. The kinase 
adds a phosphate group to the protein by hydrolyzing an ATP-molecule. A 
phosphatase removes the phosphate group, reconstituting the native conformation of 
the protein. 
 
 
The family of protein kinases includes a high number of diverse proteins that are 
specialized for a single protein or for a certain group of proteins. The same specificity 
can be found in phosphatases that also dephosphorylate a defined target or a group 
of targets. In the healthy cell the degree of phosphorylation and dephosphorylation is 
kept in an accurate balance (Alberts et al, 2002). 
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3. Protein kinases: Regulators of cell growth 
 
 
Mitogen Activated Protein Kinases (MAP-Kinases, MAPKs) are involved in the control 
of many cellular programs, such as embryogenesis, proliferation, differentiation and 
cell death (Lewis et al, 1998). Nearly 20 MAPKs were found in mammals, which show 
a high sequence identity (Caffrey et al, 1999). A few examples are the extracellular 
signal-regulated kinases 1 and 2 (ERK1/2), c-Jun N-terminal kinase (JNK(1-3)) and 
p38 (α, β, γ and δ) families. ERK3, ERK5 and ERK7 are other MAPKs that are 
differently regulated and have distinct functions (Raman et al, 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C: MAPK cascades. Illustration of the three steps of the signaling of the 
MAPK family members ERK, JNK and p38. (Raman et al, 2007) 
 
 
MAPKs are a part of signaling cascade that consists of a core of three kinases (Fig. 
C). The MAPKs get phosphorylated by the mitogen-activated protein kinase kinases 
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(MAP2K), which are activated by phosphorylation by other kinases, the MAP3Ks. 
Although the pathway seems to be a simple system, the enzymes are able to 
respond to a large number of stimuli in a remarkably specific way. The specificity is 
dependent on the kinetics of their activation and inactivation, the cellular localization, 
the formation of complexes and the availability of substrates. Furthermore scaffolding 
accessory proteins can influence and modulate the signaling components (Raman et 
al, 2007). 
MAPKs, MAP2Ks and MAP3Ks are all inactivated by the specific removal of 
phosphate from either the tyrosine or the threonine. This dephosphorylation is 
catalyzed by three major groups of protein phosphatases based on preference for 
dephosphorylation of phospho-tyrosine, phospho-serine/threonine, or both types of 
phosphoresidues (dual-specificity phosphatases (DSP, DUSP) (Cobb et al, 1999). 
Thus, phosphoprotein phosphatases act on all parts of MAPK cascade, they can 
function both ways, activating or suppressing. 
DUSPs are sharing a similar structure and sequence with protein tyrosine 
phosphatases (PTPs) and contain the conserved consensus site “HCX5R”, but they 
have different kinases as a substrate in vitro and in vivo. A subgroup of the DUSPs is 
called MAPK phosphatases (MKPs) because they specifically act on MAPK family 
members (Camps et al, 2000). 
 
 
3.1. The ERK1/2 MAPK Pathway 
 
 
ERK1 and ERK2 (Fig. D) are highly identical proteins that are ubiquitously expressed 
and play an important role in the regulation of a high number of cellular processes 
like proliferation, differentiation, survival, cell adhesion, angiogenesis and chromatin 
remodelling (Yoon et al, 2006). Through the activation of p90 ribosomal S6 kinase 
(RSK), mitogen and stress activated kinase (MSK) and MAPK interacting kinase 
(MNK) ERK1/2 are involved in cell attachment and migration, and they also 
phosphorylate the transcription factors Elk-1 (Ets related proto-oncogene), c-Fos 
(FBJ murine osteosarcoma viral oncogene homolog), c-Myc (myelocytomatosis viral 
oncogene homolog) and Ets domain factors among many others. ERK1/2 get 
activated by growth factors, serum, phorbol esters and ligands for heterotrimeric G 
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protein-coupled receptors, cytokines, transforming growth factors, osmotic and other 
kinds of cell stress, and microtubule depolymerization. Depending on the stimulus 
ERK1/2 are involved in different cellular responses like cell motility, proliferation, 
differentiation and survival (Chen et al, 2001; Johnson et al, 2002). 
 
 
 
Figure D: Three-dimensional structure of ERK2. The active site of protein kinases 
are formed at the interface of the two folding domains. ATP is represented in the 
ERK2 active site. Phosphorylation sites (Y185 and T183) within the activation loop, 
the MAPK insert, the common docking domain (CD domain), helix C, and the C-
terminal extension, L16, are indicated. (Chen et al, 2001) 
 
 
The MAP2Ks acting upstream of ERK1/2 are the dual specificity ERK Kinases 1 and 
2 (MEK1 and MEK2), which phosphorylate tyrosine and threonine in the ERK1/2 
activation loops. In this pathway the different v-Raf-1 Murine Leukemia Viral 
Oncogene Homolog (Raf) isoforms (A-Raf, B-Raf and C-Raf (Raf-1)) are the main 
MAP3Ks activating MEK1/2. Like other MAP3Ks they phosphorylate two serine 
residues or a serine and a threonine residue in the activation loop of the MAP2Ks. 
The Raf family members are activated by a combination of binding to and 
phosphorylation by small G proteins of the Rat Sarcoma Viral Oncogene Homolog 
(Ras) family (Rapp et al, 2006).  
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Another example for a MAP3K is Tumor Progression Locus 2 (Tpl2) which is able to 
activate ERK1/2, c-Jun N-terminal Kinase (JNK), p38 and ERK5 by the 
phosphorylation of their upstream MAP2Ks depending on the kind of stimulus 
(Chiariello et al, 2000). 
 
 
3.1.1 ERK1/2 proteins 
 
ERK1 and ERK2 are highly similar proteins. Their kinase domain sequences are also 
related to the sequences of other MAPKs like Raf-1 and MEK1 (Fig. E). 
ERK1/2 localize throughout the cell. 50% of ERK1/2 of the cell are bound to 
cytoplasmic microtubules where they influence the polymerization dynamics to the 
cytoskeleton (Reszka et al, 1995). ERK1/2 are also associated at adherens junctions 
and focal adhesions, where they play a role in the regulation of cell-cell and cell-
matrix adhesion (Ishibe et al, 2004).  
 
 
 
Figure E: Related kinase domain structure of MAPKs. Top: Raf-1. Raf-1 protein 
consists of a kinase domain and two cystein-rich domain (CR1 and CR2). The 
phosphorylation sites that are activating Ras are indicated by an asterisk (*). Middle: 
MEK1. Next to the kinase domain, MEK1 consists of a proline rich sequence and a 
nuclear export signal (NES). MEK1 gets activated by phosphorylation sites in the 
activation loop. Bottom: ERK2. ERK2 shows 80% similarity to ERK1. The picture 
indicates the kinase domain, the common docking domain (CD) and the C-terminal 
extension (L16) (Chen et al, 2001). 
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Upon activation by growth factors and other ligands ERK1/2 translocate into the 
nucleus where they can access nuclear transcription factors and other nuclear 
proteins to be activated or stabilized. As a consequence the expression of diverse 
genes is modified. The localization of ERK1/2 in the cell is strictly regulated. MEK1 is 
known to be an important regulator for the ERK1/2 distribution. MEK1 protein has a 
nuclear export signal (NES) and serves as a shuttle for ERK1/2 by binding it and 
being exported in associated form (Adachi et al, 2000). Both, active and inactive 
ERK1/2 can be transported into the nucleus by a passive process which involved the 
binding of ERK1/2 to DEF motif (FXF repeats, ERK and FXFP docking motif) of 
nucleoporins in the nuclear pore complex (Matsubayashi et al, 2001). In addition 
phosphorylated ERK1/2 can be actively transported into the nucleus (Ranganathan 
et al, 2006). 
 
 
3.1.2. The specificity of ERK1/2 interactions 
 
MAPKs contain docking motifs and reciprocal interaction motifs that play a crucial 
role for the specificity in MAPK signaling. The common docking motif (CD motif) is a 
cluster of positively charged residues with at least two hydrophobic residues next to it 
and it is located N-terminal to the characteristic serine/threonine/proline 
phosphorylation site that is phosphorylated by ERK1/2 (Tanoue et al, 2001). Another 
motif found in ERK1/2 substrates is the DEF motif. Elk-1, Serum Response Factor 
Accessory Protein 1 (SAP-1), c-Fos and the Scaffold Kinase Suppressor of Ras 
(KSR) contain this motif (Jacobs et al, 1999) (Chang et al, 2002).  
Another way how the specificity of the interactions of ERK1/2 is determined is the 
regulation of signalling by scaffold proteins. Scaffolding proteins are assembling 
certain components of the MAPK cascade to initiate the action of their target proteins 
to start the signalling cascade (Elion et al, 2001; Kolch et al, 2005; Morrison et al, 
2003). Scaffolding proteins were first discovered in the yeast pheromone mating 
pathway, where Pheromone-Response Scaffold Protein (Ste5p) assembles a MAPK 
module that gets coupled with cytoskeletal components of the cell. Ste5p does not 
exist in higher eukaryotes, but there is a number of other binding proteins that fulfil 
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similar function. Scaffolds for the ERK1/2 pathway are MEK Partner-1 (MP1) and 
Arrestin-β1 (ARB1).  
The role of the most scaffolds in regulating ERK1/2 is not clearly established. MP1 for 
example is known to initiate the formation of ERK complexes upon Epidermal Growth 
Factor (EGF) stimulation (Teis et al, 2002). 
Another way how the activity of MAPKs is influenced is the action of MAPK 
phosphatases (MKPs), which selectively dephosporylate MAPKs. These 
phosphatases belong to the family of dual-specificity phosphatases, what means, 
that they are able to dephosphorylate serine/threonine residues as well as tyrosine 
residues (Owens et al, 2007). 
Partially the specificity of ERK signalling may be also due to temporal variation in the 
strength and localization of ERK (Murphy et al, 2006). A constitutive but not transient 
ERK signalling induces genes involved in cell-cycle entry, like Cyclin D1, and 
represses genes involved in the inhibition of proliferation (Yamamoto et al, 2006). But 
if ERK signalling is too high elevated, the cell goes into cell-cycle arrest by the 
stabilization of Cdk-inhibitors like p27 and p21. These mechanisms are important in 
the development of cancer, where deregulation of the MAPK signalling plays an 
important role. Obviously the balance between the strength of ERK signalling and 
appropriate negative feedback loops is fundamental to avoid the induction of cell-
cycle arrest, but it also indicates, that some MAPK inhibitors could induce 
tumorigenesis (Sewing et al, 1997; Woods et al, 1997). 
 
 
3.4. The role of MAPKs in cancer development 
 
A high percentage of cancers show a deregulation of the MAPK pathways, indicating 
their important role in tumorigenesis. The development of a tumor requires a number 
of mutations in the cell in order to acquire certain abilities. These are: high 
proliferative property also without growth factors, mechanisms to avoid apoptosis, 
insensitivity of anti-growth signals, telomerase activity for unlimited replication, the 
ability to metastasize and to induce vascularization for nutritient supply (Hanahan and 
Weinberg, 2000). 
Deregulation of the ERK pathway is involved in 30% of human cancers. In particular 
the signalling which is activated through growth factors is important in that context. 
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Most of these mutations are concerning the apex of the pathway, that includes the 
overexpression of growth factor receptors, a higher supply of activating ligands, and 
mutations of Ras and Raf. In addition also a high number of transcription factors were 
found to be over-activated in cancers, like Myc and Activator Protein 1 (AP-1) 
(Giancotti et al, 1999). 
Mutated Ras shows a higher activating property by a decreased ability of hydrolysing 
the guanosine triphosphate (GTP), leading to a constitutively active state (Hancock et 
al, 2005; Mor et al, 2006). 
In the Raf family, only B-Raf has a high tumorigenic potential. Mutated B-Raf, 
showing a mutation in the activation loop leading to a elevated catalytic activity, is 
present in two third of human malignant melanomas (Davies et al, 2002; Wan et al; 
2004). 
The three Raf family members have different activating ability for MEK1 and MEK2, 
where B-Raf was shown to have the highest potential for MEK1/2 phosphorylation 
(Marais et al., 1997; Wu et al., 1996). 
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4. Protein phosphatases 
 
 
The family of protein phosphatases consists of three distinct gene families. These 
families differ in a high degree in structure and function, but catalytic domains are 
highly conserved within the families (Table A). The members belonging to one 
phosphatase family have a common conserved catalytic domain, but they are gaining 
diversity by the addition of different functional domains and regulatory subunits. 
These domains are influencing different features of the protein, including the 
specificity, the location or the folding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A: Nomenclature of protein phosphatase families: The PPP and PPM 
families of phosphatases are exclusively dephosphorylating phosphoserine and 
phosphothreonine residues. The family of PTP proteins is divided into tyrosine-
specific phosphatases and dual-specificity phosphatases (DSPs, DUSPs). DSPs are 
able to dephosphorylate tyrosine, as well as serine and threonine residues (Barford 
et al, 1998). 
 
Catalytic subunit Regulatory subunits
PP1c GM, GL, M110 + M21, NIPP-1, RIPP-1, R110, p53BP2, L5, sds22, RB gene product, 
inhibitor-1, CARPP-32, inhibitor-2, splicing factor, kinesin-like protein, γ134.5 (Herpes simplex), R5 
PP2Ac A subunit (PR65)
B subunit (PR55, PR72, PR61), eRF1, PTPA, SET, polyoma middle and small T antigens, SV40 small T antigen
PP2B B subunit, calmodulin, AKAP-79
Novel protein phosphatases of the PPP family
PPP1: PPY, Ppz1, Ppz2, Ppq1
PP2A: PP4, PP6, PPV 6A, sit4, Ppc1, Ppg1
PPP5: PP5, RdgC
Nomenclature of protein phosphatases
PPP family
PPM family
PTP family
RR2C
Arabidopsis ABI1
Arabidopsis KAPP-1
Pyruvat dehydrogenase phosphatase
Bacillus subtilis SpoIIE phosphatase
Tyrosine-specific phosphatases
Cytosolic, nonreceptor forms
PTP1B, SHP-1, SHP-2
Receptor-like transmembrane forms
CD45, RPTPµ, RPTPα
Dual-specificity phosphatases
CDC25
Kinase-associated phosphatase
MAP kinase phosphatase-1
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The protein phosphatase gene families are the phosphoprotein phosphatases (PPP), 
Mg2+- or Mn2+-dependent protein phosphatases (PPM) and protein tyrosine 
phosphatases (PTP). PPPs and PPMs are serine/threonine phosphatases, which are 
dephosphorylating their substrates by a single reaction using a metal-activated 
nucleophilic water molecule. 
The PTP family includes two subgroups: the first subgroup, the classical PTPs, is 
exclusively dephosphorylating phosphotyrosine residues, whereas the dual-specificity 
phosphatase (DSP, DUSP) group of PTPs is able to dephosphorylate all three 
phospho-amino acid types (Barford et al, 1998). 
To be able to understand the complex balance of phosphorylation that is kept by 
both, protein kinases and protein phosphatases, it is necessary to understand more 
about the specificity of these proteins, their regulation and their catalytic 
mechanisms. 
 
 
 
4.1. The family of PTPs 
 
 
PTPs play a fundamental role in cellular processes like cell growth, differentiation, 
cell cycle, metabolism and cytoskeletal function. Together with PTKs they are 
determining the phosphorylation state of tyrosine residues (Tonks et al, 2001). The 
imbalance of these functions was shown to be associated with human diseases like 
autoimmunity, diabetes and cancer (Blume-Jensen, 2001; Tonks et al, 2001). 
PTPs are defined by their signature motif C(X)5R, and consist of two subgroups: the 
tyrosine-specific, classical PTPs, and second, the dual specificity phosphatases 
(DUSPs, DSPs) (Andersen et al, 2004). 
The cystein residue in the phosphatase-binding loop of classical PTPs is responsible 
for the nucleophilic action during dephosphorylation by accepting the phosphate 
group (Guan et al, 1991). 
The recognition of the phosphate group takes place in the phosphotyrosine 
recognition loop, where the the depth of the active site creates the selectivity for 
phosphotyrosine. Phosphoserine and phosphothreonine amino acid side groups are 
too short to be dephosphorylated in a PTP catalytic site. (Jia et al, 1995). 
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The second group, the DSP group, is able to dephosphorylate tyrosine, serine and 
threonine residues as well as inositol phospholipids (Andersen et al, 2004). 
 
 
4.1.1. The genomic distribution of PTPs 
 
Until today 38 different human PTP genes have been identified. These genes are 
nonrandomly distributed in the genome, forming clusters on certain chromosomes. 
The largest accumulations of PTP genes can be found on chromosome 1 and 12 
(Fig. F), but they are absent from chromosomes X and Y and also from 
chromosomes 16, 17, 21 and 22. On chromosomes 5, 8 and 13 only PTP 
pseudogenes were found.  
 
 
 
 
Figure F: PTP related sequences in the human genome: Localization of PTP 
genes (blue), intronless pseudogenes (green) and pseudogenes containing intron 
sequences (pink) in the human chromosomes (Andersen et al, 2004).  
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Highly similar PTPs, like T Cell PTP (TCPTP) and PTP1B, PTPD1 and PTPD2 or 
PTPα and PTPε rarely share one chromosome, although they highly probably arose 
from a gene duplication of one ancestral PTP gene. Just chromosome 12 is 
harboring 2 groups of highly identical PTPs: SH2 Domain Containing Phosphatase 1 
(SHP1 and SHP2), the two PTPs sharing the feature carrying a SH2 domain, and 
three family members of the Receptor Type PTPβ (RPTPβ) proteins, namely RPTPβ, 
Glomerular Epithelial Protein 1 (GLEPP1) and PTPS31 (Andersen et al, 2004), what 
possibly could be an indication for a shared regulation or similar functions. 
 
 
4.1.2 The PTP gene organization 
 
A number of exons of genes encoding PTPs are ranging from 9 (Hematopoietic PTP 
(HePTP), the smallest PTP, consisting of 339AA) to 47 (Basophile PTP (PTP-BAS), 
the largest PTP, consisting of 2466AA). In addition, there are remarkable differences 
in the sizes of the PTP genes. The most compact PTP gene encodes SHP1 in 16 
exons spanning only 9960 bp. The largest PTP sequence belongs to RPTPρ, whose 
32 exons are spread over 1117166bp, although the resulting protein is only the ninth 
largest in the PTP family. 
The sequences encoding the catalytic domains (spanning 6-9 exons) of the PTPs are 
harboring very short introns, compared to the introns found in the sequence of 
noncatalytic regions or extracellular parts (Andersen et al, 2004; Lim et al, 2001). The 
conserved sequence motifs, that characterize the PTP family of proteins (Andersen 
et al, 2004), are not interrupted by introns, except an intron interrupting the 
phosphatase domains in all transmembrane PTPs and in most nontransmembrane 
PTPs. The fact that some nontransmembrane PTPs do not show this motif splitting 
indicates an early evolutionary divergence of these proteins (Besco et al, 2001). The 
transmembrane segment of receptor-type PTPs, which follows the "positive inside" 
rule, is encoded by a single exon, supporting the hypothesis of gene assembly by 
exon shuffling (Fedorov et al, 2001, Koshi et al, 1999).  
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4.1.3. PTPs and diseases 
 
Diabetes type 2 and obesity were associated with 10 confirmed susceptibility loci in 
the human genome. 4 PTPs have been suscepted to be involved in the development 
of these diseases, but only PTP1B was proven to be (Ghosh et al, 1999).  
Mutated forms of CD45, a transmembrane receptor-like PTP expressed in 
hematopoietic cells (Trowbridge et al, 1994), was found in patients suffering from 
severe combined immunodeficiency (SCID), suggesting the important role of CD45 in 
the activation of T and B cells (Kung et al, 2000 ; Majeti et al, 2000). In addition a 
silent single nucleotide polymorphism (SNP) in exon 4 of CD45 has been shown to 
participate in the development of multiple sclerosis (Jacobsen et al, 2000). 
Another example for disease related phosphatases is SHP2, whose function is to 
mediate growth factor and cytokine induced ERK1/2 phosphorylation (Saxton et al, 
1997). Mutations in SHP2 sequence causing an inactive SHP2 protein have been 
reported to be involved in Noonan syndrome, a disease showing symptoms like heart 
malformation, short stature, learning problems, skeletal malformations, impaired 
blood clotting and characteristic facial dysmorphia. In addition, SHP2 mutation have 
been shown to play a role in inherited juvenile myelomonocytic leukemia (JMML), 
where it causes sustained ERK1/2 activation (Tartaglia et al, 2001).  
Initially PTPs were just considered to counteract kinases, leading to an important role 
as potential tumor suppressors. But the functions of the diverse protein phosphatases 
appear to be more diverse. For example PTPα is able to activate Src kinase by itself, 
what can lead to cell transformation (Zheng et al, 1992). An example for a protein 
tyrosine phosphatase that was shown to function as a tumor suppressor in several 
kinds of human cancer is Density Enhanced Phosphatase (DEP-1) (Ruivenkamp et 
al, 2002). 
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5. Density Enhanced Phosphatase 1 (DEP-1) 
 
 
Density Enhanced Phosphatase 1 (DEP-1; also known as CD148, Human PTP eta 
(HPTPη) and PTP Receptor-Type J (PTPRJ)) was first discovered in 1994 by two 
independent groups. (Honda et al, 1994; Ostman et al, 1994).  
Honda et al (1994) isolated DEP-1 mRNA, consisting of 4780 bp, from human 
placenta. This sequence encoded a protein tyrosine phosphatase composing an 
extracellular region of 970 amino acids, a transmembrane region of 25 amino acids, 
and an intracellular region of 342 amino acids.  
The intracellular domain of DEP-1 contains only one single catalytic domain, while 
most of the proteins belonging to the tyrosine phosphatase family contain two 
catalytic domains, even if one of them is inactive in most of the cases. Another 
characteristic of DEP-1 is a tandem repeat of multiple fibronectin-typeIII-repeats 
(FNIII-repeats) in the extracellular domain, which indicate a possible role of DEP-1 in 
cell-adhesion processes (Fig. G) (Honda et al, 1994). 
 
 
Phosphatase
1
TMFN FN FN FN FN FN FN FN
1337
FN Fibronectin type-III repeats
TM Transmembrane part
 
 
Figure G: Protein structure of DEP-1. Eight FNIII-repeats at the extracellular 
domain, a short transmembrane domain, and an intracellular phosphatase domain. 
 
 
This feature classifies DEP-1 as a type III PTP, according to the classification for 
receptor-type PTPs by Fischer et al (Fischer et al, 1991). In this group of proteins 
DEP-1 shows a high similarity to SAP-1 and PTP10D.  
Depending on the cell type the transfection of full-length DEP-1 leads to protein 
signals in western blot that are ranging from 180kDa to 250kDa. When these 
transfected cells are treated with tunicamycin or N-glycosidase F the signal shifts to 
approximately 140kDa, which fits the predicted molecular weight of DEP-1 calculated 
according to the amino acid sequence. These findings support the conclusion that 
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the different molecular weights of DEP-1 that are observed in western blotting are 
mostly due to N-linked glycosylations at the 34 potential glycosylation sites. (Honda 
et al, 1994; Ostman et al, 1994).  
The DEP-1 gene is located at the short arm of chromosome 11 (11p11.2) (Honda et 
al, 1994), which is a region that is frequently lost or deleted in diverse human 
carcinomas like breast or liver carcinoma (Ali et al, 1987; Wang et al, 1988).  
Ostman et al (1994) identified DEP-1 in a HeLa cell library. Like Honda et al, they 
characterized the protein as a RPTP containing several glycosylation sites and FNIII 
repeats in the extracellular segment. In addition, they hypothesized the function of 
DEP-1 in contact inhibition of cell growth, because of their observation in experiments 
with cultured fibroblasts, where DEP-1 expression and activity dramatically increased 
in dense cultures (>25,000 cells/cm²) relative to sparse cultures (<7000 cells/cm²). 
Because of these findings they proposed the name “high cell density enhanced 
protein tyrosine phosphatase 1” for the enzyme (Ostman et al, 1994). 
FNIII repeats are present in more than 50 different eukaryotic proteins, but most of 
these domains have no proven function. The FNIII motif number 10 in fibronectin, 
which is responsible for the adhesion process, contains the conserved motif Arginine-
Glycine-Aspartic Acid (RGD). The FNIII repeats of DEP-1 do not show this sequence 
motif, but five of them contain a XGD motif on the expected loop. This proposes a 
possible involvement in cell adhesion processes (Ostman et al, 1994). 
The amino acid sequences of the cytoplasmic domains in human, mouse and rat 
DEP-1 exhibit a high homology (>95%), but there are significant differences in the 
sequences encoding the extracellular regions in which the overall homology between 
human and mouse or rat in the extracellular domain is 65% or less with exception of 
the N-terminus and membrane proximal regions. Most obvious is a large insertion in 
the amino-terminal region of human DEP-1 that is not present in mouse or rat. Mouse 
and rat DEP-1 show a high similarity of more than 90% in the extracellular domain 
except in a 24 amino acid insertion in the mouse sequence that is not present in rat 
and a small region between amino acids 50 to 200 where the homology is 65%. 
(Zhang et al, 1997).  
Although there are remarkable differences in the amino acid sequences of human 
DEP-1 and the homologous genes in mouse and rat, they show similar structures. All 
three species show 8 FNIII repeats and 34 potential N-linked glycosylation sites in 
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the extracellular domain (Zhang et al, 1997; Ostman et al, 1994; Honda et al, 1994; 
Kuramochi et al, 1996; Osborne et al, 1998; Borges et al, 1996). 
DEP-1 is a widely expressed protein. DEP-1 tissue distribution was shown by 
immunohistochemical analysis, where DEP-1 was found in columnar epithelial cells 
like those found in small and large intestinal mucosa, appendix, endometrium, 
oviducts, mammary glands, prostate glands, pancreatic acini and ducts, glandula 
parotis, sweat glands, and proximal and distal tubules of the kidneys. It is also found 
in some endocrine cells like thyroid follicular cells, parathyroid gland cells and cells in 
the islets of Langerhans in the pancreas. Additionally DEP-1 is also expressed in 
certain endothelial cells, fibrocytes/fibroblasts, Schwann cells and melanocytes. In 
contrast, neurons and ganglion cells, muscle cells and fat cells do not express DEP-1 
(Autschbach et al, 1999). 
It is present to different extent in all types of human hematopoietic cell lineages, 
where it is strongest expressed in granulocytes, followed by 
monocytes/macrophages. Weaker levels are present in peripheral blood 
lymphocytes, like CD4- and CD8-positive T-cells, B-cells, platelets, natural killer cells 
and dendritic cell types. Even less expression is found in transformed lymphoid T- 
and B-cell lines. The expression of DEP-1 in the thymus was found to be restricted to 
thymocytes and thymic endothelial cells located in the medulla (De la Fuente-Garcia 
et al, 1998).  
The homologues of DEP-1 in rat (rPTPη) and mouse (Byp) have been reported to be 
expressed in skin, stomach, pancreas, adrenal gland, placenta, lymphoid tissues, in 
lung, kidney, liver, brain and many other tissues (Zhang et al, 1997; Kuramochi et al, 
1996). 
 
Initial experiments using native and transformed rat thyroid cells demonstrated that 
DEP-1 was expressed highest in cells that showed features of normal differentiation 
like thyroglobulin synthesis and thyroid-stimulating hormone dependent growth. 
However DEP-1 expression could not be detected in cells with highly malignant 
phenotype that were lacking these differentiation markers and the expression of 
DEP-1 was shown to inhibit the growth of cancer cells (Zhang et al, 1997).  
Trapasso et al performed experiments with rat thyroid cells in which the cells were 
transfected by retroviruses and cell cycle parameters were analyzed. Malignant cells 
that were transfected with DEP-1 arrested in G1 phase in a higher extent than control 
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cells (Trapasso et al, 2000). It was found that the level of Kinase Inhibitory Protein 1 
(p27/kip-1) was increased upon transfection with DEP-1 due to a decreased protein 
degradation mediated by the 26S proteasome, which is activated by the MAPK 
pathway. Thus, the transfection of cells with DEP-1 inhibited the MAPK pathway, 
leading to decreased activation of the 26S proteasome, resulting in an increased 
half-life of p27/kip-1. (Trapasso et al, 2000; Florio et al, 2001). This effect was not 
seen in control cells transfected with an inactive form of DEP-1 that contains a 
mutation in the catalytic domain containing a serine instead of the conserved 
cysteine. In these cells the malignant phenotype could not be reversed (Trapasso et 
al, 2000). 
A loss of heterozygosity (LOH) of DEP-1 was found in 14% of thyroid tumors, 
including adenomas and carcinomas. Especially the hemizygosity for the DEP-1 
polymorphisms Gln276Pro and Arg326Gln was shown to facilitate thyroid 
carcinogenesis. These data suggest that DEP-1 is a low-penetrance tumor 
susceptibility gene concerning thyroid carcinogenesis (Iuliano et al, 2004). In 
addition, it was reported that DEP-1 coimmunoprecipitates with RET receptor 
tyrosine kinase and that RET gets dephosphorylated by DEP-1. RET gene 
rearrangements lead to the generation of chimeric RET/Papillary Thyroid Carcinoma 
(RET/PTC) oncogenes, whereas RET pointmutations occur in familial Multiple 
Endocrine Neoplasia type 2 (MEN2) and sporadic Medullary Thyroid Carcinomas 
(MTC). DEP-1 also coimmunoprecipitates with defined MEN2-type mutated RET, but 
is not able to bind RET/PTC isoforms. Thus RET/PTC mutants are resistant to the 
dephosphorylating activity of DEP-1 (Iervolino et al, 2006). 
DEP-1 is also a candidate tumor suppressor in the colon epithelium. This was shown 
by the re-introduction of DEP-1 into a DEP-1 deficient colon cancer cell line. These 
experiments showed that DEP-1 expression caused a remarkable inhibition of cell 
proliferation and cell migration (Balavenkatraman et al, 2006). 
Also other malignant cell types have been tested for the expression of DEP-1. In 
some high-grade breast carcinoma cell lines the level of DEP-1 expression was 
markedly decreased. Because DEP-1 upregulation is associated with the 
differentiation of cells, the decrease of DEP-1 expression could be an indication for 
the dedifferentiation and autonomous growth of malignant cells (Autschbach et al, 
1999). 
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DEP-1 was identified as a possible candidate for the modulation of the activity of the 
platelet-derived growth factor β receptor (PDGFβ-receptor). In porcine aortic 
endothelial cells the ligand-dependent tyrosine phosphorylation was decreased after 
transfection of a construct encoding DEP-1. A direct interaction between DEP-1 and 
PDGFβ-receptor was proven by Co-Immunoprecipitation (CoIP) (Kovalenko et al, 
2000). 
By using a substrate-trapping mutant form of DEP-1 it was demonstrated, that DEP-1 
is interacting with the Hepatocyte Growth Factor/Scatter Factor Receptor (Met). Met 
was shown to induce mitogenic, motogenic and morphogenic responses upon ligand 
activation. Disordered signaling through Met has been implicated in certain cancers. 
When Met was co-expressed with the substrate-trapping form of DEP-1, stable 
complexes were formed. Additionally, wild-type DEP-1 was found to site-selectively 
dephosphorylate Met at C-terminal tyrosines, which are involved in the recruitment of 
signaling and adaptor molecules including GRB2-Associated Binding Protein 1 
(Gab1). In contrast, tyrosine residues in the activation loop of Met were only 
dephosphorylated, when DEP-1 was expressed at high levels. This suggests, that 
DEP-1 possibly regulates Met-signaling after ligand-induction by Hepatocyte Growth 
Factor (HGF). In this context it was shown, that Growth Factor Receptor-Bound 
Protein 2 (Grb2), an interaction partner of Met, was less recruited to Met with 
increasing expression of DEP-1 (Palka et al, 2003). Interestingly, DEP-1 and Met 
share some interaction partners, these include Gab1, β-catenin, and p120 catenin 
(Palka et al, 2003; Holsinger et al, 2002). Holsinger et al. were searching for 
interaction partners of DEP-1 using a substrate-trapping mutant of DEP-1 and 
identified p120 catenin, a component of adherens junctions next to β-catenin and γ-
catenin. The interaction of DEP-1 and p120 catenin was verified by CoIP 
experiments. DEP-1 was also found to colocalize with p120 catenin at sites of cell-
cell contacts. These findings indicate an important role of DEP-1 in the generation of 
cell-cell contacts and adherens junctions through the interaction with members of the 
catenin protein family (Holsinger et al, 2002). With regard to these data, DEP-1 was 
also reported to inhibit PDGF-stimulated cell migration, by the inhibition of Ras- and 
Erk1/2-activation by PDGF. Additionally, cell-substrate adhesion was enhanced by 
DEP-1 and that could have been due to an elevated activity of Sarcoma kinase (Src) 
after cell attachment (Jandt et al, 2003). 
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In contact-inhibited endothelial cells the MAPK pathway is inhibited by DEP-1. In 
contact inhibition Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) forms a 
complex with Vascular Endothelial Cadherin (VE-cadherin). DEP-1, by binding β-
catenin and p120, could associate with the VEGFR-2-VE-cadherin complex and 
dephosphorylate the receptor. In addition, it was shown that siRNA against DEP-1 
increased VEGFR-2 phosphorylation (Lampugnani et al, 2003).  
The role of DEP-1 in somatostatin receptor (SSTR) signaling was demonstrated by 
experiments done in the rat thyroid cell line PC Cl3 in which a cell cycle arrest in G1 
by the PTP-dependent overexpression of the cyclin dependent kinase p27/kip1 was 
observed in response to somatostatin (SST). These experiments suggested that 
DEP-1 possibly acts downstream of MEK or directly on ERK1/2 (Florio et al, 2001). 
These observations have been verified by CoIP experiments in glioma cell lines 
where SST-activated DEP-1 was directly associated to dephosphorylated ERK1/2. 
Additionally, the upregulation of p27/kip-1 was seen in this context (Massa et al, 
2004). 
In PC Cl3 cells this upregulation of p27/kip-1 was found to be due to the inhibition of 
its phosphorylation by ERK1/2, what is suppressing the ubiquitination of CDKs. As a 
consequence p27/kip-1 is protected from degradation by the proteasome resulting in 
an increased half-life of the protein. (Florio et al, 2001). 
Interestingly, it was shown that the cytostatic effect of SST-stimulation required the 
expression and activation of DEP-1. In cell lines lacking DEP-1 expression, SST only 
induces G1-cell cycle arrest after reintroduction of DEP-1 by transfection, while a 
dominant-negative form does not show this effect (Massa et al, 2004).  
In CHO-K1 cells it was demonstrated that in the resting state of the cells a big 
multimeric protein cluster is formed that includes the SST-Receptor-1, the G protein, 
Janus Kinase 2 (Jak2), SHP-2, Src and DEP-1 (Arena et al, 2007). In this complex 
the G protein activates Jak2 that, in turn, phosphorylates SHP-2. Activated SHP-2 
dissociates from the receptor and dephosphorylates Src at its C-terminus. 
Dephosphorylated Src, in turn, phosphorylates DEP-1 causing the sustained activity 
of the phosphatase that dephosphorylates and inactivates ERK1/2 (Fig. H) (Arena et 
al, 2007).  
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Figure H: DEP-1 activation by somatostatin. A.: The graph shows the multimeric 
complex that is formed in resting cells. This complex includes SSTR1, G-protein, 
JAK2, SHP-2, Src and DEP-1 (PTPη). B.: SST inhibits proliferation by activation of 
DEP-1: SST binding to SSTR1 induces JAK2 phosphoprylation via G-protein. JAK2 
activates SHP-2, what leads to dephosphorylation of Src at the inhibitory site followed 
by activation by phosphorylation at T418. Src phosphorylates DEP-1 and activates it 
(Arenea et al, 2007) 
 
 
 
Similar cascades have been identified for both SST receptors (SSTR1 and 2), which 
involve a similar set of tyrosine kinases and phophatases, leading to the activation of 
an effector phosphatase (Fig. I) (Arena et al, 2007; Ferjoux et al, 2003). 
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Figure I: Somatostatin receptor pathways. Scheme demonstrating the intracellular 
cascades for the activation of the effector PTPs DEP-1 and SHP-1. (Florio et al, 
2007) 
 
 
 
Takahashi et al reported about the generation of homologous recombinant mice 
expressing mutated DEP-1, in which the intracellular domain was replaced by 
enhanced green fluorescent protein (EGFP). Homozygous mutant embryos died until 
E11.5 displaying prominent growth retardation and severe intra- and extraembryonic 
vascular anomalies (Takahashi et al, 2003).  
Until E8.25 homozygous mutant embryos do not display a disturbed phenotype, 
indicating that DEP-1 is not needed for the specification of angioblasts from the 
ventral mesoderm, their migration and their formation into major vessels. After E8.25 
first defective structures appeared, like enlarged and fused yolk sac vessels and a 
poorly formed cerebral vascular plexus. Already at E9.5 these embryos show growth 
retardation, absence of large branching vessels and an accumulation of primitive 
blood cells in the yolk sac. At E10.5 the homozygous mutant embryos are lacking 
large branching vessels in the cerebral vasculature, indicating a defective remodeling 
from the primary vascular plexus to mature vasculature. Peripheral vessels are 
enlarged and densely interconnected, and yolk sac vessels appear as oversized 
tubes formed by endothelial cells. The dorsal aorta appeared collapsed and atrophic 
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and the pericardial cavities were enlarged. Normally, endothelial cell layers attach to 
mesothelial and endodermal layers. This connection is disturbed in DEP-1 deficient 
mice (Takahashi et al, 2003). 
Homozygous mutant embryos develop a decreased number of vessels but with a 
notably larger diameter. Additionally, there is a significantly increased number of 
endothelial cells in the yolk sacs of the homozygous mutant embryos, while the 
number of endodermal cells is not increased. These observations lead to the 
hypothesis, that DEP-1 deficiency causes enhanced endothelial proliferation and 
defective endothelial-mesodermal contact formation. Perivascular structures, 
including vascular smooth muscle cells (vSMCs) and pericytes, are only sparsely 
distributed and not properly integrated. Takahashi et al hypothesized, that the 
endothelial compartment expansion in homozygous mutant embryos is caused by the 
DEP-1 deficiency resulting in a loss of growth regulation and also by additional 
growth stimulation by hypoxia-induced VEGF, that was found elevated in the mutant 
embryos. DEP-1-deficiency possibly impairs initiation or/and maturation of primary 
cell-cell contacts. Another possibility is that the elevated growth rate of the 
endothelial cells does not allow the formation of intercellular contacts (Takahashi et 
al, 2003). 
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6. Hepatitis B core-Antigen binding protein (HBCBP) 
 
 
The nucleotide and amino acid sequences of HBCBP were accessible on NCBI 
(Bethesda, MD) since 2003. The sequence of HBCBP comprises 591 basepairs and 
has the locus number AF529371. The corresponding protein sequence was 
published with the locus number AAQ09605 and has a predicted molecular weight of 
21531 Dalton. The HBCBP gene is located at chromosome 12q13.3 and does not 
contain any introns. 
Lu et al demonstrated HBCBP as an interaction partner of Hepatitis B Core Antigen 
(HBcAG) (In the paper they use the name C12, but it resembles the same gene). 
They identified the protein by an Y2H interaction study using HBcAG as bait. 
Furthermore, microarray analysis using HBCBP transfected cells indicated that the 
overexpression of HBCBP was involved in the transcription regulation of several 
genes, including Insulin Receptor (INSR) and Tumor susceptibility gene 101 
(TSG101). A Y2H screen using HBCBP as bait identified a number of potential 
binding partners that are involved in different cellular processes, like energy 
metabolism and signal transduction. (Lu et al, 2005).  
Since then, no other data dealing with this newly identified gene and protein were 
published. 
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AIMS 
 
 
After we found an interaction between DEP-1 and a newly discovered protein with an 
utterly unknown function, HBCBP, our primary aim was to find out more about this 
protein. Our first attempt was to search for a function in which the interaction between 
HBCBP and DEP-1 could be of importance. Based on the knowledge that DEP-1 
affects the cell cycle by the inhibition of MAP-Kinases we considered that HBCBP 
could also be involved in that process. We were analyzing this aspect by the use of 
Elk1-Reporter assays.  
Furthermore we wanted to proof the interaction between HBCBP and DEP-1 in the 
human system by CoIPs. In that context we also did immunostaining experiments to 
see the cellular localization of HBCBP together with DEP-1 and their possible place 
of interaction.  
After dealing with several difficulties with proving an interaction of HBCBP and DEP-1 
we used siRNA to knockdown HBCBP and DEP-1 in combination with the Elk1-
reporter system to see, if the effect the two proteins have on the MAP-Kinase 
pathway is dependent on the presence of their suspected interaction partner. 
Searching for other potential interaction partners of HBCBP that could mediate the 
effect that HBCBP has in Elk1-reporters we did CoIPs to see if HBCBP interacts with 
MEK1, ERK1/2 or DUSPs.  
To see the direct effect of HBCBP on MAP-Kinases, we wanted to see its influence of 
proliferation and apoptosis. We tested these aspects using flow cytometry.  
With the aim to find hints for the purpose of HBCBP we analyzed multi-tissue panels 
for differences in the extent of the expression of the protein. For the same reason we 
wanted to analyze a hypothetical HBCBP promoter for potential regulatory sites that 
could indicate in which processes the protein could be involved. In addition we tried 
to find out more about the protein by the use of different software-programs to make 
predictions about its evolutionary descent, potential functional domains and 
phosphorylation sites. 
In addition we tried to purify recombinant HBCBP for the purpose of the generation a 
polyclonal antibody. 
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METHODS 
 
 
1. Plasmids and Constructs 
 
pCMV-Myc-HBCBP: Full-length HBCBP was amplified using the (5’ GCC CGA ATT 
CGG ATG ATA AGT GAA GGC GGA TGG GGA TGG CAG GGG 3’) containing an 
EcoRI restriction site and the reverse primer (5’ GCT CGT CGA GCC TCG AGC 
AGC CTA CTT GTT AAC AGA GGA CTT TTT TGT TTC ATC 3’) with a XhoI 
restriction site. The product was cloned between the EcoRI and XhoI site in the 
pCMV-Myc plasmid (Invitrogen, Carlsbad, CA). This vector was used to overexpress 
HBCBP in human cell cultures. 
Truncated HBCBP constructs: Primers were designed to amplify the N-terminal, the 
middle, or C-terminal third of the full-length HBCBP sequence. All forward primers 
contained EcoRI restriction sites and all reverse primers contained SalI sites. For the 
N-terminal part (∆73-196) of HBCBP (pCMV-Myc-HBCBP∆73-196) the forward 
primer (5’CGA ATT CGA ATG ATA AGT GAA GGC GGA TGG GGA TGG CAG G3) 
and the reverse primer (5’CGG TCG ACC CAG CTA TGA GGA GCT GAC TCT GGG 
ACA ACT C3’) were used. For the middle part (∆1-62;140-196) of HBCBP (pCMV-
Myc-HBCBP∆1-62;140-196) the forward primer (5’CGA ATT CGG GAG TTG TCC 
CAG AGT CAG CTC CTC ATA GCT G3’) and the reverse primer (5’CGG TCG ACC 
GGT GCC GGG GAC AGA GGG TGA AGG AGA GAG3’) were used. For the C-
terminal part (∆1-139) of HBCBP (pCMV-Myc-HBCBP∆1-139) the forward primer 
(5’CGA ATT CGG CTC TGT CCT TCA CCC TCT GTC CCC GGC ACC3’) and the 
reverse primer (5’GGT CGA CCC TAC TTG TTA ACA GAG GAC TTT TTT GTT TCA 
TC3’) were used. The products were cloned between the EcoRI and SalI restriction 
site of pCMV-Myc plasmid (Invitrogen, Carlsbad, CA).  
pEGFP-C1-HBCBP : The full-length sequence of HBCBP was amplified from pCMV-
Myc-HBCBP using the forward primer (5’ CGA GCG AAT TCT GCA ATG ATA AGT 
GAA GGC GGA TGG GGA TGG 3’) containing an EcoRI restriction site and the 
reverse primer (5’ CGC GGA TCC CTT CTA CTT GTT AAC AGA GGA CTT TTT 
TGT TTC 3’ ) with BamHI restriction site. The product was cloned between the EcoRI 
and BamHI restriction site in the pEGFP-C1 plasmid (Clontech, Paolo Alto, CA). This 
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vector was used to overexpress HBCBP in human cell cultures for microscopy 
experiments. 
pET24a-HBCBP: Full-length HBCBP was amplified using the forward primer (5’ GCC 
CGA ATT CGG ATG ATA AGT GAA GGC GGA TGG GGA TGG CAG GGG 3’) 
containing an EcoRI restriction site and the reverse primer (5’ GCC TCG AGC AGC 
CTT GTT AAC AGA GGA CTT TTT TG 3’) containing an XhoI restricition site. The 
product was cloned between the EcoRI and XhoI site in the pET24a vector 
(Novagen, Darmstadt, D) containing a pentameric His-tag at the 3’ end of the cloned 
sequence. The vector was used for expression in bacteria with the purpose of 
purification. The purified protein aimed to be an antigen for antibody production. 
All constructs were confirmed by sequencing with ABI Prism® Big Dye™ Terminator 
Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA) on 310 
Genetic Analyzer (Perkin Elmer, Wellesley, MA) 
pSRα-CD148/HA and pSRα-CD148∆cyto vectors, to overexpress HA-tagged DEP-1 
or non-tagged DEP-1 truncated for its cytoplasmic domain, were previously 
described. The vector pSRα-CD148/HA was used to overexpress full-length DEP-1 in 
all following experiments (Takahashi et al, 2006). 
Reporter vectors: Vectors from the PathDetect trans-reporting system were 
purchased from Stratagene (La Jolla, CA). These vectors were pFR-Luc (trans-
reporting Luciferase plasmid) and pFA2-Elk1. The PathDetect System was modified 
for the Dual-Luciferase Reporter-System by the use of the reference vector pRL-CMV 
(Promega, Madison, WI).  
The Nur77 overexpression plasmid pcDNA3.1-Nur77 (1-598 amino acids, full length, 
wt) were described previously (Gruber et al, 2003).  
 
 
2. Cell Culture 
 
Human Embryonic Kidney 293 cells (HEK293), Hepatocellular Carcinoma cells 
(HepG2), LNCaP cells (Prostate epithelial cancer cell line) and RWPE1 cells 
(Prostate epithelial cell line) were obtained from ATCC (Manassas, VA) and cultured 
as recommended. Human Umbilical Vein Endothelial Cells (HUVECs) were cultured 
as previously described (Gruber, F., 2003) and used until the 5th passage. Treatment 
with different stimuli was done with cells that reached approximately 80% confluency, 
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if not stated differently. Reagents used for stimuli were: phorbol 12-myristate 13-
acetate (PMA, Sigma, St. Louis, MO), transforming growth factor β1 (TGFβ1, 
BioSource International, Camarillo, CA), Interferon-α (IFNα, R+D Systems, Inc., 
Minneapolis, MN), Interferon-γ (IFNγ, R+D Systems, Inc., Minneapolis, MN), tumor 
necrosis factor α (TNFα, Merck, Darmstadt, D), WY14643 (Biomol, Hamburg, D), 
Rosiglitazone-maleate (Alexis biochemicals, Lausen, CH) and Prostaglandin E2 
(PGE2, Sigma, St. Louis, MO). When stimulating with substances dissolved in 
dimethyl sulfoxide (DMSO), the control cells were also treated with the corresponding 
amount of DMSO. HEK293 were transiently transfected for luciferase reporter assays 
or other experiments using calcium–phosphate-protocol (Perkins et al, 1993) and 
1.5µg DNA per well in 6-well plates or 1µg DNA in 12-well plates and chamber slides. 
HepG2 cells were transfected using Lipofectamine Plus Reagent (Invitrogen, 
Carlsbad, CA) according to manufacturer’s protocol. In experiments with transfected 
cells, the cells were used for experiment 48 hours after transfection, in the confluent 
state, if not indicated differently. Stimulations on transfected cells were done in the 
subconfluent state. Transfections in combination with siRNA into HEK293 and 
HepG2 cells were done using polyethylenimin (PEI, Sigma, St Louis, MO). For the 
transfection of one 12-well 3µl of vortexed PEI (35µM, pH 7.0) were mixed with 
46.5µl of 2xHeBS buffer (280mM NaCl, 1.5mM Na2HPO4, 50mM Hepes, pH 7.05). In 
a second tube 5µl of siRNA (20µM) or scrambled control RNA and expression 
vectors were mixed with 46.5µl of 2xHeBS. The two solutions were mixed together 
and incubated in the dark at room temperature for 20min. The media on the cells was 
removed and 400µl of serum free media were added. 100µl of transfection mix were 
added per 12-well and incubated for 3 hours and then exchanged to serum 
containing media. The cells were used for experiment 48 hours after transfection, if 
not indicated differently. SiRNAs were purchased from Ambion (Foster City, CA). The 
HBCBP siRNA sense strand was (AGU AUC AAG GGA UGU CAU UdTdT) and the 
antisense strand was (AAU GAC AUC CCU UGA UAC UdTdT), and the DEP-1 
siRNA sense strand was (GCA GUA CAG CAG AAU CCU UdTdT) and the antisense 
strand was (AAG GAU UCU GCU GUA CUG CdTdT). 
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3. Co-Immunoprecipitations (CoIPs) 
 
HEK293 cells were seeded in 6-wells. The next day the cells were transiently 
transfected with pCMV-Myc-HBCBP and/or pSRα-CD148/HA to overexpress Myc-
HBCBP and/or HA-DEP-1. 48 hours later, the cells were lysed for 30min in 350µl/6-
well of CoIP cell lysis buffer (2.7mM KCl, 1.5mM KH2PO4, 9.2mM Na2HPO4 2H2O, 
150mM NaCl, 0.7% NP40, 0.3% Triton X-100 and Complete Protease Inhibitor 
Cocktail (Roche Diagnostics, Basel, Switzerland)). 3 6-wells were used for 1 sample. 
Lysates were centrifuged to remove cell debris. At this stage whole cell lysate (WCL) 
aliquots were taken to check protein expression. Where indicated, the NaCl 
concentration in the cell lysate was increased by the addition of 2M NaCl, otherwise 
the cell lysate contained 150mM NaCl present in the Lysis Buffer. When Sepharose 
beads were used, 2µg of antibody were added to the cell lysate and rotated at 4°C 
for 30min. Then 20µl of Sepharose beads were added (for mouse antibodies – 
protein G-Sepharose, for rabbit antibodies – protein A-Sepharose (Amersham 
Biosciences, Buckinghamshire, UK), and further incubated at 4°C for 3.5 hours.  
In the case of Dynabeads M-280 Tosylactivated (Invitrogen, Carlsbad, CA), the 
antibody to be linked was dialyzed in 0.1M borate buffer pH9.5 for 3 hours. 
Dynabeads were prepared and covalently linked with the antibody according to the 
manufacturer’s protocol. 15µl of linked Dynabeads were used for one sample and 
incubated for 4 hours at 4°C. 
Then the beads were washed 3 times with PBS and then resuspendend in Laemmli 
buffer, vortexed and heated to 95°C for 10min. The supernatants were collected and 
subjected to western blot. Antibodies used for CoIP-pull down were mouse anti-
CD148 (Invitrogen, Carlsbad, CA), mouse anti-Myc (Oncogene, San Diego, CA), 
rabbit anti-EGFP (Abcam, Cambridge, UK), rabbit anti-MKP-3 (anti-DUSP6, Santa 
Cruz Biotechnology, Santa Cruz, CA), rabbit anti-MKP-4 (anti-DUSP9, Santa Cruz 
Biotechnology, Santa Cruz, CA), rabbit anti-HA (Santa Cruz Biotechnology, Santa 
Cruz, CA) and the control antibodies normal mouse IgG (Santa Cruz Biotechnology, 
Santa Cruz, CA), rabbit immunoglobulin fraction (DAKO, Milan, Italy). All CoIP-
experiments were repeated at least 3 times. 
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4. Interaction on ELISA-plates 
 
HEK293 cells were seeded in 6-wells. The next day the cells were transiently 
transfected with p-CMV-Myc-HBCBP and/or pSRα-CD148/HA. 48 hours after, the 
cells were lysed for 30min in 350µl/6-well of CoIP cell lysis buffer (2.7mM KCl, 
1.5mM KH2PO4, 9.2mM Na2HPO4 2H2O, 150mM NaCl, 0.7% NP40, 0.3% Triton X-
100 and Complete Protease Inhibitor Cocktail (Roche Diagnostics, Basel, 
Switzerland)). Lysates were centrifuged to remove cell debris. Microtiter plates (Nunc 
maxisorp; Nunc, Roskilde, Denmark) were coated with 4µg/ml rabbit anti-DEP-1 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) or rabbit immunoglobulin 
fraction in 100mM NaHCO3 buffer, pH 9.3 at 4°C overnight. In uncoated wells 
NaHCO3 buffer was used without antibodies. The wells were blocked with 1% BSA in 
PBS for 2 hours at 37°C and then 100µl of cell lysate were applied and incubated for 
4 hours at 37°C. The wells were incubated with mouse anti-Myc antibody in 0.5% 
BSA in PBS (1µg/ml) for 1 hour at 37°C and then further with second peroxidase-
coupled anti-mouse antibody (1µg/ml) (Amersham Biosciences, Buckinghamshire, 
UK). Inbetween all these incubation steps the wells were washed 3 times with 0.5% 
Tween 20 in PBS. Then 100µl ABTS solution containing 1g/l diammonium 2,2-
Aazino-di-(3-ethylbenzothiazoline-6-sulfonate) (Roche Diagnostics, Basel, 
Switzerland), 77 mM Na2HPO4, 60 mM C6H8O7, 1 mL/L H2O2 was added to the wells. 
The reaction was stopped with 100 µl 0.32% NaF and the absorbance at 405 nm was 
determined using an ELISA reader (EL 808 Ultra Microplate Reader, Bio-TEK 
Instruments). To determine non-specific binding of Myc-HBCBP uncoated wells were 
used.  
 
 
5. Western blotting 
 
Cells were lysed in 1x Laemmli buffer for 10min, and additionally sonicated. The 
lysates were heated to 95°C for 10min before use. These samples or collected 
samples from CoIPs were subjected to 10% SDS-polyacrylamide gel electrophoresis 
(SDS-page) and transferred by western blotting to a polyvinylidene difluoride 
membrane (Millipore, Bedford, MA). First antibodies that were used are indicated in 
figure legends. Detection of immunoreactive bands was done by the use of second 
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HRP-linked antibodies and ECL-Plus reagent (Amersham Biosciences, 
Buckinghamshire, UK) according to manufacturers protocol. For anti-phospho-Serine 
(anti-P-Ser) and anti-phospho-Threonine (anti-P-Thr, Sigma, St. Louis, MO), which 
are biotinylated antibodies, we used Streptavidin-HRP (Becton Dickinson, Franklin 
Lakes, NJ) as second step to visualize the protein. 
 
 
6. Immunostaining 
 
HEK293 were grown to 50-80% confluency in chamber slides (Nalge Nunc 
International, Naperville, IL) and transfected with pEGFP-C1-HBCBP and pSRα-
CD148/HA or pSRα-CD148∆cyto. The cells were fixed in 4% paraformaldehyde, 
afterwards permeabilized with Triton X-100 and then stained HA-DEP-1 and ∆cyto-
DEP-1 with mouse anti-CD148 (Invitrogen, Carlsbad, CA) at a dilution of 1:300 and 
Alexa fluor 568 conjugated goat anti-mouse second antibody in 1:300 dilution 
(Molecular Probes, Eugene, Oregon). Presence of enhanced green fluorescent 
protein (EGFP) from the transfected vector pEGFP-C1-HBCBP was determined on a 
LSM510 confocal laser microscope (Zeiss, Germany) at 488nm excitation and 512nm 
emission wave length and separated from the Alexa Fluor 568 label (excitation 
wavelength 543nm, emission wavelength 630nm).  
 
 
7. Flow Cytometry 
 
HepG2 cells were grown in 6-wells to approximately 50% confluency and then 
transfected with scrambled RNA or siRNA to knock down HBCBP as described 
above. For BrdU assay, the cells were stained according to the protocol of BrdU Flow 
Cytometry Assay Kit (BD Biosciences, Franklin Lakes, NJ). For Ki67 analysis the 
cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% Tween20 in 
PBS and blocked with 1% BSA in PBS. The cells were stained with FITC-labeled 
anti-Ki67 (Invitrogen, Carlsbad, CA) in a dilution of 1:300. For AnnexinV analysis the 
cells were stained according to the protocol of ApoAlert® Annexin V-FITC Apoptosis 
Kit (Clontech, Paolo Alto, CA). For the propidium iodide (PI) analysis the cells were 
scraped of the dish and resuspended in 1%BSA containing PBS. The cells were 
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stained with PI (Sigma, St. Louis, MO) in a concentration of 1µg/ml for 10 min. For all 
the flow cytometry experiments the cells were analyzed using FACSort machine 
(Becton Dickinson, Franklin Lakes, NJ). The data sets were analyzed with FCS 
Express V3 program.  
 
 
8. Promotor analysis 
 
The genomic sequence that was analyzed was reaching -900 to +300 bp from the 
transcription start of HBCBP (1200bp). The sequence was analyzed using the 
MatInspector software (Genomatix, Munich, D), a software tool that utilizes a large 
library of matrix descriptions for transcription factor binding sites to locate matches in 
DNA sequences. In this analysis the matrix group of vertebrates was preselected. 
The list that resulted from this analysis was used to search for active transcription 
factor binding sites that regulate HBCBP expression. 
 
 
9. Quantitative Real-Time PCR (Q-PCR) 
 
Human Multi-Tissue RNA Panel and Multi-tissue cDNA Panel were purchased from 
Clontech (Paolo Alto, CA). The samples from the RNA panel were reverse 
transcribed. Placenta tissue was kindly provided by Semmelweis Frauenklinik 
(Vienna, A). HepG2 cells or HUVECs were grown to subconfluency in 6-well plates 
and treated with different stimuli as indicated. LNCaP cells and RWPE1 cells were 
seeded in 6-well plates and grown to confluency. RNA from these cells was extracted 
using TRIzol reagent (Invitrogen, Carlsbad, CA). Total RNA (900ng) was reverse 
transcribed with MuLV reverse transcriptase using the Gene Amp RNA PCR kit 
(Applied Biosystems, Foster City, CA) and d(T)16 primers. The mRNA sequences 
from the genes to be analyzed were obtained from GenBank. The primers were 
designed using the PRIMER3 software (Whitehead Institute for Biomedical Research, 
Cambridge, MA). The following forward (“F”) and reverse (“R”) primers were used for 
human HBCBP: F 5’ CTG GGT CAG CAG GAT GGT AT 3’ and R 5’ CCG AAG CTG 
GTA AGA GGT CA 3’. Q-PCR was performed by Light Cycler technology using the 
Fast Start SYBR Green I kit for amplification and detection (Roche Diagnostics, 
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Basel, Switzerland). In all assays cDNA was amplified using a standardized program 
(10’ denaturating step and 55 cycles of 5’’ at 95°C, 15’’ at 65°C, and 15’’ at 72°C, 
melting point analysis in 0.1°C steps, final cooling step. Each LightCycler capillary 
was loaded with 1.5 µl of DNA Master Mix, 1.8 µl MgCl2 (25 mM), 10.1 µl H2O, and 
0.4 µl of each primer (10 µM). The final amount of cDNA per reaction corresponded 
to 2.5 ng total RNA used for reverse transcription. Reverse quantification of target 
gene expression was performed using a mathematical model by Pfaffl (Pfaffl et al, 
2001). The expression of the target molecule was normalized to the expression of 
human porphobilinogen deaminase (PBGD) using the primers: F’ 5´-TCG AGT TCA 
GTG CCA TCA TC- 3´ and PBGD R’ 5´-CAG GTA CAG TTG CCC ATC CT-3’. 
 
 
10. Reporter Assays 
 
The PathDetect Elk1 trans-reporting system (Stratagene, La Jolla, CA) was modified 
for the Dual-Luciferase Reporter-System (Promega, Madison, WI) to quantify Elk1-
activation according to the manufacturer’s instructions. For the PathDetect reporter 
system HEK293 cells were transfected in 12-wells with 200ng/well with plasmids 
containing the genes of interest (volume adjusted with pCMV-Myc empty plasmid) 
and 600ng/well reporter plasmid mixture (80% pFR-Luc, 10% pFA2-Elk1, 10% pRL-
CMV) using calcium-phosphate method (cell-culture paragraph). 48h after 
transfection the cells were lysed and used for analysis. In experiments including 
siRNA, the reporter vectors were combined with 5µl of 20µM siRNA or control siRNA 
and the mix was transfected using PEI protocol mentioned in cell-culture paragraph. 
In reporter assays using siRNA 72 hours after transfection the cells were lysed and 
used for analysis. The cell lysates were subjected to dual luciferase assays according 
to manufacturer’s protocol (Promega, Madison, WI) on a Victor luminometer (Wallac, 
Turku, FIN). Photinus luciferase activity was normalized to Renilla luciferase activity. 
 
 
11. Recombinant HBCBP 
 
One colony of the bacteria strain BL2(DE)pLysS (Novagen, Darmstadt, D) 
transformed with pET24a-HBCBP was inoculated into LB-media containing 50µg/ml 
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ampicillin and 34µg/ml chloramphenicol and grown overnight at 37°C. In the morning 
the culture was diluted to an apprimate OD600 of 0.2 and then further grown to an 
OD600 of 0.6. Expression of the recombinant protein was induced by addition of 1mM 
isopropyl-beta-D-thiogalactopyranoside (IPTG) at 30°C for 3hours. Aliquots of the 
culture were also taken at the timepoints 0, 1 and 2 hours. The cells were pelleted 
and resuspended in PBS containing 1mM phenylmethylsulfonylfluorid (PMSF) as 
protease inhibitor. After sonication and spinning, the supernatant was collected in 
fresh tubes and diluted 1:1 with 2x Laemmli buffer and the pellet was resuspended in 
1x Laemmli buffer (contains inclusion bodies). The samples were subjected to 
Western blot. 
 
 
12. In silico analysis:  
 
ClustalW2 (EMBL-EBI, Sanger Institute, Hixton, UK): The ENSEMBL homepage 
(Sanger Institute, Hinxton, UK) provided predicted orthologues of human HBCBP in 5 
different species (chimpanzee, elephant, armadillo, guinea-pig and lesser hedgehog 
tenrec). The ClustalW2 software was used to compare the amino acid sequences of 
these predicted orthologues to human HBCBP. This program is used to analyse 
similarities of amino acid sequences and therefore serves to find hints for 
evolutionary descent.  
 
Block Searcher analysis (Fred Hutchinson Cancer Research Center, Seattle 
Washington, USA): The Block Searcher is an aid to detect and verify a protein 
sequence homology. It compares a protein or DNA sequence to a database of 
protein blocks. It is looking for the most highly conserved regions in groups of 
proteins. We submitted the complete 196 amino acid sequence of human HBCBP to 
achieve information about possibly related proteins. The resulting sequences are 
listed showing combined E-values (Expect-values) that indicated the probability of 
relationship. 
 
SMART: (Simple Modular Architecture Research Tool, Heidelberg, Germany): The 
program allows the identification and annotation of genetically mobile domains and 
the analysis of domain architectures. It detects more than 500 domain families found 
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in signalling, extracellular and chromatin-associated proteins. These domains are 
exclusively annotated with respect to phyletic distributions, functional class, tertiary 
structures and functionally important residues. We submitted the full-length amino 
acid sequence of HBCBP to the program to achieve domain information about the 
protein. The result is presented in a list. 
 
ELM-EMBL analysis of HBCBP-Amino-Acid sequence: The ELM server (The 
Eukaryotic Linear Motif resource for Functional Sites in Proteins, Heidelberg, 
Germany) is a computational biology resource for investigating candidate functional 
sites in eukaryotic proteins. The current version of the ELM server provides core 
functionality including filtering by cell compartment, phylogeny, globular domain clash 
(using the SMART/Pfam databases) and structure. In addition, both the known ELM 
instances and any positionally conserved matches in sequences similar to ELM 
instance sequences are identified and displayed. We used this program to analyze 
the amino acid sequence of HBCBP for conserved domain patterns. 
 
PredPhospho (National Genome Research Institute, Seoul, Korea): PredPhospho is 
a program that predicts phosphorylation sites in primary protein sequences. We used 
this program to find possible phosphorylation sites in HBCBP and therefore we 
submitted the full-length amino acid sequence.  
 
NetPhos 2.0 Server (Technical University of Denmark, Lyngby, Denmark): This 
program produces predictions for serine, threonine and tyrosine phorphorylation sites 
in eukaryotic proteins. We used this program to have a second guess on possible 
phosphorylation sites in HBCBP. Also here we analyzed the entire amino acid 
sequence of HBCBP. 
 
Statistical analysis: All experiments were done at least twice. Experimental values 
are expressed as means ± standard error of the mean (SEM). Statistical significance 
of differences was analyzed by student’s t-test. 
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RESULTS 
 
 
1. Regulation of ERK1/2 MAP-Kinase pathway 
 
 
Since DEP-1 is known to influence the activity of MAP-Kinases, we were interested, if 
HBCBP could also play a role in the regulation of these pathways. For that purpose 
we used the PathDetect Elk1 trans-reporting system (Stratagene, La Jolla, CA), and 
modified the protocol for the Dual-Luciferase Reporter-System (Promega, Madison, 
WI). The PathDetect Elk1 trans-reporting system includes a transactivator plasmid 
leading to the expression of a trans-acting transcription activator that consists of the 
activation domain of Elk-1 fused with the DNA binding domain of yeast GAL4. The 
pFR-Luc reporter plasmid of the PathDetect system contains a synthetic promoter 
with five tandem repeats of the yeast GAL4 binding site that control the expression of 
Photinus pyralis (American firefly) luciferase gene. Upon phoshorylation the DNA 
binding domain of the Elk1 fusion trans-activator protein binds to the reporter plasmid 
at the GAL4 binding sites and starts transcription of the luciferase gene. Influences 
on the phosphorylation level of the Elk1 fusion transactivator protein thus influence 
the expression level of Luciferase and reflect the activation status. Elk1 gets 
phosphorylated by ERK1/2, thus representing a read out for the activity of the 
ERK1/2 MAP-Kinase pathway. 
The reporter plasmids were transfected into HEK293 cells in combination with 
HBCBP and/or DEP-1. Cells were confluent when they were harvested.  
Overexpression of DEP-1 (pSRα-CD148/HA) reduced significantly the transcriptional 
activity of Elk-1. Similarily HBCBP overexpression (pCMV-Myc-HBCBP) inhibited the 
reporter system. Overexpression of both, HBCBP and DEP-1, had an additive effect 
(Fig. 1.1.1.). As a positive control PMA as a general enhancer of MAP-Kinase activity 
was used, that highly increased the Elk-1 activity evidencing that the reporter system 
worked (1.1.2.). 
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Fig 1.1. Reporter assay on P-elk: Myc-HBCBP and/or HA-DEP-1 were overexpressed in 
HEK293 cells in combination with Elk-1 Reporter constructs (1). As a positive control cells 
were stimulated with PMA (50nM) overnight (2). Both, Myc-HBCBP and HA-DEP-1 inhibited 
the activity of Elk-1 and also acted additive when cotransfected. Pool of 12 values, graph 
shows means ± SEM. Statistics calculated using Student‘s t-test versus control value (*** 
P<0.005). 
 
 
 
To further analyze the HBCBP effect, we did a titration of the pCMV-Myc-HBCBP 
vector on the Elk1-PathDetect system. As already shown in Fig.1.1.1., DEP-1 and 
HBCBP reduced Elk1 activity. When half (100ng/12well) or a quarter (50ng/12well) 
the amount of HBCBP vector was used, the inhibitory activity was lower, a further hint 
for the specificity of this reporter system (Fig.1.2.). 
 
 
 
 
 
 
 
 
Fig. 1.2. Reporter assay on P-elk: Graph shows a titration of p-CMV-Myc-HBCBP vector in 
combination with Elk-1 reporter constructs and HA-DEP-1 in HEK293 cells. The down-
regulation of Elk-1 activity due to Myc-HBCBP overexpression correlated to the amount of 
Myc-HBCBP transfected. Pool of 10 values, graph shows means ± SEM. Statistics calculated 
using Student‘s t-test (* t-test P<0.05; *** t-test P<0.005). 
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To further test the specificity of the Elk1-reporter system, we also analyzed truncated 
HBCBP constructs. All three truncated HBCBP constructs pCMV-Myc-HBCBP∆73-
196, pCMV-Myc-HBCBP∆1-62;140-196 and pCMV-Myc-HBCBP∆1-139 did not show 
an inhibitory effect on Elk1, further indicating the specificity of the HBCBP effect 
(Fig.1.3.). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3. Reporter assay on P-elk: Elk-1 reporter constructs and HA-DEP-1 were 
cotransfected in combination with p-CMV-Myc-HBCBP or truncated Myc-tagged HBCBP 
constructs (pCMV-Myc-HBCBP∆73-196, pCMV-Myc-HBCBP∆1-62;140-196, pCMV-Myc-
HBCBP∆1-139). Myc-HBCBP and HA-DEP-1 downregulated the activity of Elk-1 and acted 
additive when coexpressed. In contrast, the truncated Myc-HBCBP constructs did not affect 
Elk-1 activity, indicating the HBCBP effect to be specific. Pool of 10 values, graph shows 
means ± SEM. Statistics calculated using Student‘s t-test (n.s. (not significant) t-test P>0.05; 
*** t-test P<0.005). 
 
 
The activity of DEP-1 is known to depend on the cell density. Thus, we were 
interested whether the inhibitory effect of HBCBP on Elk1 depended on cell density 
as well. In the experiments shown previously, only cells that were grown to a dense 
layer were used. For this set of experiments, cells were seeded in different densities 
(10000; 25000; 40000 cells/cm2) and then they were transfected with the Elk1-
PathDetect vectors in combination with Myc-HBCBP and/or HA-DEP-1. Cells were 
harvested when the first set of cells was still sparse, the second set subconfluent and 
the third set fully confluent. Like in the experiments before, Myc-HBCBP showed 
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inhibitory activity on Elk-1 in the confluent set of cells. In the subconfluent set of cells 
Myc-HBCBP showed a less inhibiting effect on Elk-1 and that was even more 
prominent in the set of sparse cells (Fig. 1.4.), indicating that the activity of HBCBP is 
dependent on the density of the cells. This would correlate to an increasing 
expression of DEP-1 with an increasing density of the cells, as it was detected 
previously in fibroblasts (Ostman et al, 1994). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.4. Reporter assay on P-elk: HEK293 cells seeded in different densities as indicated. 
Overexpression of Myc-HBCBP and/or HA-DEP-1 in HEK293 cells in combination with Elk-1 
Reporter constructs. Cells were harvested 2 days after seeding when the 10000n/cm² set of 
cells was still sparse, the 25000n/cm² set reached medium confluency and the 40000n/cm² 
set of cells were fully confluent. In the fully confluent set of cells Myc-HBCBP and DEP-1 
inhibited the activity of the Elk-1 reporter system. The inhibitory effect on Elk-1 by Myc-
HBCBP was less pronounced in the set of subconfluent cells and was absent in the set of 
sparsely grown cells. Pool of 14 values, graph shows means ± SEM. Statistics calculated 
using Student‘s t-test versus control (n.s. t-test P>0.05, *** t-test P<0.005). 
 
 
 
Further, we wanted to test whether the expression of HBCBP could be influenced by 
the cell density. If that was true, certain experiments could only work when cells are 
in certain cell densities. For that purpose we used HUVECs, a primary cell line that 
does not have an altered gene expression or regulation due to malignancy or 
transformation, and seeded them in different densities (10000 / 25000 / 40000 
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n/cm²). We analysed HBCBP expression by QPCR when cells reached the desired 
densities (sparse – subconfluent – confluent). HBCBP expression increased 
correlating to cell density, although the increase was not significant (Fig.1.5.). 
 
 
 
 
 
 
 
 
 
 
Fig. 1.5. Expression analysis of HBCBP in HUVECs cells at different cell densities: HUVECs 
cells were seeded in 6-wells in different densities (10000 / 25000 / 40000 n/cm²). When cells 
reached the desired densities (sparse – subconfluent – confluent) the cells were harvested. 
The expression of HBCBP was not significantly influenced by different density states of the 
cells. Values were normalized to PBGD. Pool of values from 2 independent experiments. 
Graph shows means ± SEM.  Statistics calculated using Student‘s t-test (n.s. t-test >0.05). 
 
 
 
Another idea was that HBCBP expression could be altered upon cell malignancy due 
to their different proliferation regulation concerning cell-cell contact inhibition. 
Therefore, we wanted to compare the expression rate of HBCBP in a normal cell line 
with its corresponding cancer form. For that purpose we used LNCaP cells, deriving 
from a metastatic prostate epithelial carcinoma, and RWPE1, a normal prostate 
epithelial cell line (containing a single copy of human papilloma virus 18 (HPV-18) for 
immortalization), to compare the expression rate by QPCR, but we could not detect 
significant differences (Fig.1.6.). 
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Fig. 1.6. Expression analysis of HBCBP in normal versus cancer cells: LNCaP (prostate 
epithelial cancer cells) and RWPE1 (prostate epithelial cells, immortalized with HPV-18) were 
seeded in 6-wells. In the confluent state the cells were harvested. Malignancy of the prostate 
cell line did not significantly influence the expression rate of HBCBP. Values were normalized 
to PBGD. Pool of values from 2 independent experiments. Graph shows means ± SEM.  
Statistics calculated using Student‘s t-test (n.s. t-test >0.05). 
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2. Interaction of HBCBP with DEP-1 
 
 
The interaction of HBCBP and DEP-1 was shown previously by a yeast-two-hybrid 
experiment in my diploma thesis. In the present thesis, we were interested, if the 
interaction of HBCBP and DEP-1 could also be shown in the mammalian system. For 
this purpose, we used the method of CoIP. Therefore, we overexpressed Myc-tagged 
HBCBP and HA-tagged DEP-1 alone or in combination in a human cell line 
(HEK293). Cells were harvested in the confluent state. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1. CoIP: HEK293 cells overexpressing Myc-HBCBP and/or HA-DEP-1. CoIP using 
Protein G Sepharose and anti-Myc antibody (Oncogene, San Diego, CA) in 350mM NaCl-
concentration. Samples were applied to WB and developed with anti-DEP-1 antibody 
(Invitrogen, Carlsbad, CA). Expression of Myc-HBCBP and DEP-1 (overexpressed HA-DEP-
1 and endogenously expressed DEP-1) are shown in whole cell lysate (WCL) aliquots. IP of 
Myc-HBCBP was confirmed by developing with anti-Myc antibody, but DEP-1 was not 
coprecipitated. Representative of three independent experiments. 
 
 
At first we tried to co-precipitate DEP-1 with HBCBP by the use of Protein G 
Sepharose and anti-Myc antibody in a lysate with 350mM NaCl concentration. To 
demonstrate the expression of Myc-HBCBP and HA-DEP-1, aliquots of the whole cell 
lysate (WCL) were taken. For the CoIP first the anti-Myc antibody was added to the 
lysate and preincubated before the Sepharose G was added. After further 3.5 hours 
of incubation, the beads were washed with PBS and finally dissolved in Laemmli-
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buffer, heated and pelleted by centrifugation. The samples were applied to SDS-
Page and Western blot and anti-Myc antibody showed that Myc-HBCBP was 
successfully overexpressed and also precipitated. To see, if DEP-1 (endogenous and 
ectopic) was co-precipitated with HBCBP the membrane was developed with anti-
CD148. HA-DEP-1 was also successfully transfected but did not appear to be co-
precipitated (Fig.2.1). 
 
 
 
Then, less stringent conditions were used for CoIP (150mM NaCl), because higher 
salt-concentrations can inhibit weak protein interactions. But also in the less stringent 
condition DEP-1 was not co-precipitated with HBCBP (Fig.2.2.). 
 
 
 
 
 
 
 
 
 
 
Fig. 2.2. CoIP: HEK293 cells overexpressing Myc-HBCBP and/or HA-DEP-1. CoIP with 
Protein G Sepharose and anti-Myc antibody in 150mM NaCl-concentration. Samples were 
applied to WB and developed with anti-DEP-1 antibody. Expression of Myc-HBCBP and 
DEP-1 (overexpressed and endogenous) are shown in WCL aliquots. IP of Myc-HBCBP was 
confirmed by developing with anti-Myc antibody, but DEP-1 was not coprecipitated. 
Representative of three independent experiments. 
 
 
 
Reciprocally, anti-CD148 was used to co-precipitate HBCPB. In this set we first used 
the 350mM NaCl concentration. Similar to the experiments shown before, the 
expressions of HBCBP and DEP-1 were shown in the WCL aliquots. In the CoIP 
samples it could be shown that DEP-1 was precipitated by the anti-CD148 antibody, 
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however Myc-HBCBP did not co-precipitate (Fig.2.3.) and also in the less stringent 
150mM NaCl condition anti-CD148 antibody did not co-precipitate Myc-HBCBP 
(Fig.2.4.). 
 
 
 
 
 
 
 
 
 
 
Fig. 2.3. CoIP: HEK293 cells overexpressing Myc-HBCBP and/or HA-DEP-1. CoIP with 
Protein G Sepharose and anti-CD148 antibody (Invitrogen, Carlsbad, CA) in 350mM NaCl-
concentration. Samples were applied to WB and developed with anti-Myc antibody. 
Expression of Myc-HBCBP and DEP-1 (overexpressed and endogenous) are shown in WCL 
aliquots. IP of DEP-1 was confirmed by developing with anti-CD148 antibody, but Myc-
HBCBP was not coprecipitated. Representative of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.4. CoIP: HEK293 cells overexpressing Myc-HBCBP and/or HA-DEP-1. CoIP with 
Protein G Sepharose and anti-CD148 antibody in 150mM NaCl-concentration. Samples were 
applied to WB and developed with anti-Myc antibody. Expression of Myc-HBCBP and DEP-1 
(overexpressed and endogenous) are shown in WCL aliquots. IP of DEP-1 was confirmed by 
developing with anti-CD148 antibody, but Myc-HBCBP was not coprecipitated. 
Representative of three independent experiments. 
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Finally we performed CoIP using Dynabeads. Before the beads were used for the IP 
they were covalently linked to antibody (mouse anti-CD148 antibody and normal 
mouse IgG as control). Also in these experiments Myc-HBCBP and DEP-1 
expressions were confirmed in the WCL. DEP-1 was precipitated with the CD148 
antibody (endogenous DEP-1 and also overexpressed HA-DEP-1) and Myc-HBCBP 
was co-precipitated with it. But similar bands appeared also in the control IP using 
normal mouse IgG, while DEP-1 did not co-precipitate. This result indicated that this 
pull down was not specific (Fig.2.5.) 
 
 
 
 
 
 
 
 
 
 
Fig. 2.5. CoIP: HEK293 cells overexpressing Myc-HBCBP and/or HA-DEP-1. CoIP with 
Dynabeads covalently linked to anti-CD148 antibody with a cell lysate containing 150mM 
NaCl-concentration. Samples were applied to WB and developed with anti-Myc antibody. 
Expression levels of Myc-HBCBP and DEP-1 (overexpressed and endogenous) are shown in 
WCL aliquots. IP of DEP-1 was confirmed by developing with anti-CD148 antibody. HBCBP 
coprecipitated in samples using anti-CD148 antibody, but similarly it was also detected in 
samples, where normal mouse IgG were used as a control, indicating that the positive result 
was unspecific. Representative of three independent experiments. 
 
 
 
Next also Sepharose-CoIPs using an anti-EGFP antibody with cells overexpressing 
EGFP-tagged HBCBP and/or HA-DEP-1 were performed and also with anti-HA 
antibody for cells overexpressing HA-DEP-1 and/or Myc-tagged HBCBP. In both 
experimental setups it was not possible to coprecipitate Myc-HBCBP with DEP-1, 
even in the lowest stringency conditions (data not shown). 
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After it appeared, that the CoIPs did not work out with Sepharose and Dynabeads, 
we tried a different approach using ELISA-plates coated with anti-CD148 antibody. 
Cell lysates containing overexpressed Myc-HBCBP and/or HA-DEP-1 were applied 
and incubated. Then anti-Myc antibody was added and subsequently second anti-
mouse-POX antibody. Similarly to the previous CoIP-experiments, Myc-HBCBP 
bound to the same extent to the wells containing overexpressed HA-DEP-1 as to the 
wells containing only endogenously expressed DEP-1. In addition the same pattern 
appeared in wells in which normal mouse IgGs were coated and also in the non-
coated wells, indicating that Myc-HBCBP not only bound unspecifically to the normal 
IgG but also to the microtiter plate (Fig.2.6.). 
 
 
 
 
 
 
 
 
 
 
Fig. 2.6. Interaction on ELISA-plates: Microtiter plates were coated with polyclonal anti-DEP-
1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Then cell lysate containing 
overexpressed Myc-HBCBP and/or HA-DEP-1 was applied to the wells. Using an anti-Myc 
antibody we analysed, if Myc-HBCBP bound to the microtiter plates by binding to DEP-1 
(overexpressed and endogenous). The results indicated that Myc-HBCBP not only bound in 
wells coated with anti-DEP-1 antibody, but also in wells coated with rabbit immunoglobulin 
fraction as a control and even to non-coated wells, indicating that the result was unspecific. 
Representative of three independent experiments, graph shows means ± SEM of triplicates. 
Statistics calculated using Student‘s t-test (n.s. P>0.05; * P<0.05). 
 
 
 
Next, to investigate a potential cellular localization of HBCBP and a possible 
colocalization of HBCBP and DEP-1, we transfected HEK293 cells in chamber slides 
to overexpress EGFP-tagged HBCBP in combination with HA-DEP-1 or ∆-cyto-DEP-
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1. The slides were stained with anti-CD148 antibody and second Alexa 568 antibody 
(red). Images were taken using LSM510 microscope (Zeiss, Germany). EGFP-
tagged HBCBP (green) was homogenously spread in the cytoplasm. In contrast, 
EGFP alone was localized in all compartments of the cell (also in the nucleus, data 
not shown). This indicated that also endogenous HBCBP is excluded from nucleus. 
DEP-1 is a transmembrane phosphatase and so HA-DEP-1 and ∆-cyto-DEP-1 could 
be visualized at the cell membrane (red). Concerning colocalization of EGFP-HBCBP 
and HA-DEP-1, there were slight yellow traces next to the cell membrane in the 
merge picture. But when comparing, the same picture could be seen in the samples 
transfected with mutant ∆cyto-DEP-1, indicating that the slight colocalization was not 
specific and probably only due to overexpression and the proximity of the cellular 
compartments in which the proteins are located (Fig. 2.7.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.7. Co-Localization: HEK293 cells in chamber slides transfected with pEGFP-C1-
HBCBP and pSRα-CD148/HA (HA-DEP-1) (Fig. 2.7.1) or pSRα-CD148∆cyto (∆cyto-DEP-1) 
(Fig. 2.7.2). Slides were stained with mouse anti-CD148 antibody (Invitrogen, Carlsbad, CA) 
and Alexa Fluor 568 conjugated anti-mouse second antibody (Molecular Probes, Eugene, 
Oregon) (red); green resembles EGFP-HBCBP. Pictures were taken using Confocal 
microscope. Picture showed a slight colocalization of EGFP-HBCBP with wt-DEP-1 in 
proximity to the cell membrane, but a similar merge picture could be seen when EGFP-
HBCBP was coexpressed with ∆cyto-DEP-1, indicating, that the colocalization was not 
specific. Representative of three independent experiments. 
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3. How does HBCBP affect Elk1 activity? 
 
 
To further investigate the inhibitory effect of HBCBP on Elk-1 we wanted to see if the 
inhibitory effect of HBCBP was dependent on the presence of DEP-1 and also vice 
versa. For that purpose we used the Elk-1 reporter system in combination with 
overexpression of Myc-HBCBP and/or HA-DEP-1 and in addition silencing of HBCBP 
and DEP-1 by siRNA. In scrambled RNA transfected control cells, Myc-HBCBP, like 
HA-DEP-1, reduced significantly the transcriptional activity of Elk-1, and 
overepression of both had an additive effect. When HBCBP was silenced, the effect 
of Myc-HBCBP was abolished, but HA-DEP-1 still downregulated the Elk-1 effect. 
Similarly, when DEP-1 was silenced, the HA-DEP-1 effect was abolished, but Myc-
HBCBP still downregulated the Elk-1 effect. These results indicated that both 
inhibitory effects, of Myc-HBCBP and HA-DEP-1, did not depend on the presence of 
the other protein (Fig.3.1.). Representative samples were used for the verification of 
the silencing of HBCBP and DEP-1 by Q-PCR (data not shown). 
 
 
 
 
 
 
 
 
 
Fig. 3.1. Elk-1 Reporter with HBCBP/DEP-1 knockdown: Reporter assay on P-elk in HEK293 
overexpressing Myc-HBCBP and/or HA-DEP-1. Silencing of DEP-1 or HBCBP with siRNA 
(siDEP-1/siHBCBP). In scrambled RNA control (scr) Myc-HBCBP and HA-DEP-1 
downregulated the activity of Elk-1 and when cotransfected, the effect was additive. When 
DEP-1 was silenced, the inhibitory effect of HA-DEP-1 was abolished, but Myc-HBCBP still 
decreased Elk-1 activity. Similarly, when HBCBP was silenced, the Myc-HBCBP effect was 
abolished, but the HA-DEP-1 effect remained. That indicated that the inhibitory effects of 
both, Myc-HBCBP and HA-DEP-1 did not depend on the presence of the other protein. Pool 
of 8 values, graph shows means ± SEM. Statistics calculated using Student‘s t-test (n.s. t-
test >0.05; * t-test P<0.05; ** t-test P<0.01; *** t-test P<0.005). 
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Therefore we tested if HBCBP overexpression has an effect on the phosphorylation 
state of ERK1/2 at all. We transfected HEK293 cells with Myc-HBCBP. The cells 
were harvested with Laemmli buffer and applied to SDS-page and Western blots. 
The membrane was developed with anti-phospho-ERK1/2 antibody and anti-total-
ERK1/2 antibody. The intensity of P-ERK1/2 was decreased compared to control 
upon HBCBP overexpression. Experiments were repeated for several times. 
Although the difference of ERK1/2 phosphorylation was not significant when 
analyzing the western blots by densitomentry, the trend was always a reduction of 
ERK1/2 phosphorylation in presence of overexpressed HBCBP (Fig.3.2.). 
 
 
 
 
 
 
 
 
Fig. 3.2. Influence of HBCBP on ERK1/2 phosphorylation: HEK293 cells were transfected 
with pCMV-Myc-HBCBP vector. Cells were harvested with Laemmli-Buffer. Samples were 
applied to SDS-Page and Western blot. Membranes were developed with anti-P-ERK1/2 and 
anti-total-ERK1/2 (Cell Signaling Technology, Inc., Danvers, MA). Anti-Myc-developing 
confirmed successful pCMV-Myc-HBCBP transfection. Myc-HBCBP expression reduced the 
phosphorylation state of ERK1/2, although the decrease was not significant. Representative 
of three independent experiments. 
 
 
 
After we knew that the inhibitory effect of Myc-HBCBP on the ERK1/2 MAP-Kinase 
pathway was not dependent on the presence of DEP-1, we wanted to look for a 
possible interaction partner of HBCBP that could mediate the effect. First we wanted 
to see by CoIP, if HBCBP possibly interacts with MEK-1, the upstream kinase of 
ERK1/2. For that purpose we used Protein G Sepharose and anti-Myc antibody in a 
lysate containing overexpressed Myc-HBCBP with 150mM NaCl concentration. The 
whole-cell-lysate aliquots showed the successful transfection of Myc-HBCBP and the 
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endogenous level of MEK-1. Myc-HBCBP was precipitated in the CoIP, but MEK-1 
did not coprecipitate (Fig.3.3.1.). 
 
 
 
 
 
 
 
Fig. 3.3.1. Interaction of HBCBP with MEK1: HEK293 were transfected with p-CMV-Myc-
HBCBP. CoIP was done with Protein G Sepharose and anti-Myc antibody with lysates 
containing low-salt concentration. Samples were applied to SDS-Page and Western blot, 
developed with anti-MEK1 antibody (Cell Signaling Technology, Inc., Danvers, MA). 
Expression of overexpressed Myc-HBCBP and endogenously expressed MEK1 were shown 
in WCL aliquots. IP of Myc-HBCBP was confirmed by developing with anti-Myc antibody, but 
MEK1 was not coprecipitated. Representative of three independent experiments.  
 
 
In a similar way we checked, if HBCBP interacted with ERK1/2. Again Myc-HBCBP 
was precipitated in the CoIP, but ERK1/2 did not coprecipitate (Fig.3.3.2.). 
 
 
 
 
 
 
 
 
Fig. 3.3.2. Interaction of HBCBP with ERK1/2:  HEK293 were transfected with p-CMV-Myc-
HBCBP. CoIP was done with Protein G Sepharose and anti-Myc antibody with lysates 
containing low-salt concentration. Samples were applied to SDS-Page and Western blot, 
developed with anti-total ERK1/2 antibody (Cell Signaling Technology, Inc., Danvers, MA). 
Expression of ectopic Myc-HBCBP and endogenously expressed ERK1/2 were shown in 
WCL aliquots. IP of Myc-HBCBP was confirmed by developing with anti-Myc antibody, but 
ERK1/2 was not coprecipitated. Representative of three independent experiments.  
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Another possibility was that HBCBP interacted with certain MAP-Kinase 
Phosphatases (MKPs) that are known to influence the activity of the ERK1/2 
pathway. For that purpose we checked if Myc-HBCBP coprecipitated with two 
cytoplasmic MKPs, DUSP6 and DUSP9 (Dual-Specificity Phosphatases 6/9). We 
used Protein A Sepharose and anti-DUSP6 or anti-DUSP9 antibodies. As a control 
rabbit immunoglobulin fraction was used. The whole-cell-lysate aliquots showed the 
overexpressed Myc-HBCBP and the endogenously expressed DUSP6 and DUSP9. 
DUSP6 and DUSP9 were precipitated, but Myc-HBCBP was not coprecipitated 
(Fig.3.3.3.). 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3.3. Interaction of HBCBP with DUSPs: HEK293 were transfected with p-CMV-Myc-
HBCBP (H) or control vector (C). CoIP was done with Protein-A-Sepharose and anti-DUSP6 
or anti-DUSP9 antibodies (Cell Signaling Technology, Inc., Danvers, MA) in lysates 
containing 150mM NaCl concentration. Samples were applied to SDS-Page and Western 
blot, developed with anti-Myc antibody.  Expression of overexpressed Myc-HBCBP and 
endogenously expressed DUSP6 and DUSP9 were shown in WCL aliquots. IP of DUSP6 
and DUSP9 was confirmed by developing with anti-DUSP6/antiDUSP9 antibodies, but Myc-
HBCBP was not coprecipitated. Representative of three independent experiments.  
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4. HBCBP in MAP-Kinase dependent processes 
 
 
Our previous investigations led us to the hypothesis, that HBCBP could play a role in 
the regulation of proliferation or apoptosis. To check that we used HepG2 cells 
because compared to other cell types we analyzed, these had the highest 
endogenous HBCBP expression (data not shown). In HepG2 cells HBCBP was 
silenced with siRNA and scrambled RNA was used as control. 
In order to analyze the effect on proliferation we used BrdU-assays and Ki67 staining. 
BrdU assays utilize the nucleotide Bromodeoxyuridine (BrdU), a thymidine-analogue 
that gets integrated in replicating DNA. The more cells are proliferating, the more 
BrdU gets integrated and can be detected by an anti-BrdU-antibody (Fig.4.1.).  
 
 
 
 
 
 
 
 
Fig. 4.1.1. HBCBP in proliferation: BrdU assay with HepG2 cells transfected with siRNA to 
knockdown HBCBP and scrambled RNA as control. 2 days after transfection BrdU was 
loaded onto the cells for overnight. Then, the cells were stained according to the 
manufacturers protocol (BD Biosciences, BrdU Flow Cytometry Assay Kit, FITC Detection) 
and analyzed using flow cytometry. Graph shows cells with positive BrdU staining, 
background values were obtained from control samples without BrdU loading and were 
subtracted from experimental values. Control values were set to 1. Knockdown of HBCBP 
did not have an effect on BrdU uptake to the cells. Pool of 4 values. Graph shows means ± 
SEM.  Statistics calculated using Student‘s t-test (n.s. t-test >0.05). 
Fig. 4.1.2. Knock-down control: As a control for the each BrdU experiment, a set of HepG2 
cells was treated the same way as described above, RNA was isolated and reverse 
transcribed. Expression of HBCBP was determined by quantitative real-time PCR using 
specific primers for HBCBP. Values were normalized to the housekeeping gene PBGD. 
Control values were set to 1. Graph shows means ± SEM.  Statistics calculated using 
Student‘s t-test (* t-test <0.05; *** t-test <0.005). 
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The Ki67 antigen is a marker for proliferation because it is only expressed in cells 
that are actively dividing but is completely absent from resting cells (Fig.4.2.). We 
used this approach and BrdU to analyze if HBCBP influences cell proliferation, but 
neither BrdU integration nor Ki67 staining showed a difference after HBCBP 
knockdown. 
 
 
 
 
 
 
 
 
Fig. 4.2.1. HBCBP in proliferation: Ki67 staining with HepG2 cells transfected with siRNA to 
knockdown HBCBP (siHBCBP) and scrambled RNA (Scr) as control. 3 days after 
transfection, the cells were fixed and stained with a FITC-labelled Ki67 antibody and 
analyzed using flow cytometry. Graph shows cells with positive Ki67 staining. Control values 
were set to 1. HBCBP knockdown did not affect Ki67 expression in the cells. Pool of 6 
values. Graph shows means ± SEM.  Statistics calculated using Student‘s t-test (n.s. t-test 
>0.05). 
Fig. 4.2.2. Knock-down control: As a control for each Ki67 experiment, a set of HepG2 cells 
was treated the same way as described above, RNA was isolated and reverse transcribed. 
Expression of HBCBP was determined by quantitative real-time PCR using specific primers 
for HBCBP. Values were normalized to the housekeeping gene PBGD. Control values were 
set to 1. Graph shows means ± SEM.  Statistics calculated using Student‘s t-test (* t-test 
<0.05). 
 
 
 
We used AnnexinV staining and PI staining to analyze the effect of HBCBP on 
apoptosis. AnnexinV binds to phosphatidylserine (P-Ser) that gets exposed on the 
cell surface already in early processes of apoptosis. The ApoAlert® Annexin V-FITC 
Apoptosis Kit uses FITC-labeled AnnexinV to detect these exposed P-Ser molecules 
(Fig.4.3.). Propidium iodide (PI) is an intercalating agent that is not supposed to enter 
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intact cells but enters necrotic and apoptotic cells due to their defective cell 
membrane. When excited by 488nm of laser light, it can be detected with 562-588nm 
band pass filter (Fig.4.4.). Both methods did not show a difference after HBCBP 
knockdown. The successful knockdown of HBCBP by siRNA was confirmed by Q-
PCR.  
 
 
 
 
 
 
 
 
 
Fig. 4.3.1. HBCBP in apoptosis: AnnexinV staining in HepG2 cells transfected with siRNA to 
knockdown HBCBP (siHBCBP) or scrambled RNA (Scr) as control. 3 days after transfection, 
the cells were stained using ApoAlert® Annexin V-FITC Apoptosis Kit according to 
Manufacturer’s protocol and analyzed by flow cytometry. Graph shows cells positive for 
AnnexinV staining, Control values were set to 1. Cells did not show a difference after HBCBP 
knockdown. Pool of 4 values. Graph shows means ± SEM.  Statistics calculated using 
Student‘s t-test (n.s. t-test >0.05). 
Fig. 4.3.2. Knock-down control: As a control for each AnnexinV experiment, a set of HepG2 
cells was treated the same way as described above, RNA was isolated and reverse 
transcribed. Expression of HBCBP was determined by quantitative real-time PCR using 
specific primers for HBCBP. Values were normalized to the housekeeping gene PBGD. 
Control values were set to 1. Graph shows means ± SEM.  Statistics calculated using 
Student‘s t-test (* t-test <0.05, ** t-test <0.01). 
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Fig. 4.4.1. HBCBP in apoptosis: PI-staining with HepG2 cells transfected with siRNA to 
knockdown HBCBP (siHBCBP) or scrambled RNA (Scr) as control. 3 days after transfection, 
the cells were stained with PI and analyzed by flow cytometry. Graph shows cells positive for 
PI staining, control values were set to 1. Knockdown of HBCBP does not influence the PI 
staining of the cells. Pool of 4 values. Graph shows means ± SEM.  Statistics calculated 
using Student‘s t-test (n.s. t-test >0.05). 
Fig. 4.4.2. Knock-down control: As a control for each PI experiment, a set of HepG2 cells 
was treated the same way as described above, RNA was isolated and reverse transcribed. 
Expression of HBCBP was determined by quantitative real-time PCR using specific primers 
for HBCBP. Values were normalized to the housekeeping gene PBGD. Control values were 
set to 1. Graph shows means ± SEM.  Statistics calculated using Student‘s t-test (* t-test 
<0.05, *** t-test <0.005). 
 
 
These results seem to demonstrate, that HBCBP does not influence MAP-Kinase 
activity that is related to proliferation of apoptosis. So HBCBP is possibly involved in 
other ERK1/2 related processes like cytoskeleton organization, cell adhesion or 
differentiation that we did not analyze. 
 
The verification of HBCBP knock down, that was done by Q-PCR, shows an 
increasing HBCBP expression in scrambled control compared to control in three of 
the graphs shown above. The absence of this effect in the knock-down control for the 
AnnexinV-staining indicates a difference in the transfection rate compared to the 
other experiments and therefore suggests that this result could be less substantial.   
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5. HBCBP expression in tissues 
 
 
To analyze whether the expression of HBCBP is tissue type specific and if this could 
give a hint regarding its function, a Human Multi-Tissue RNA Panel for real-time PCR 
was screened and normalized to the housekeeping gene PBGD. According to the 
crossing points of HBCBP in the samples, the gene is generally expressed in only 
low levels, but showed a major enhancement in placenta tissue (Fig.5.1). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.1. Human Multi-Tissue RNA Panel: RNA samples were reverse transcribed and 
expression of HBCBP was determined by quantitative real-time PCR using specific primers 
for HBCBP. Values were normalized to the housekeeping gene PBGD. Graph shows relative 
expression of HBCBP compared to kidney. RNA panel was composed of one sample per 
tissue. 
 
 
In order to confirm the result obtained from the RNA panel (that HBCBP expression 
levels were significantly higher in placenta tissue compared to other tissues), we 
analyzed more placenta tissue (obtained from Semmelweis Frauenklinik). The 
samples were from different weeks of pregnancy reaching from week 36 to week 42, 
representing samples from late pregnancy. From each placenta the maternal part 
and fetal part was investigated (data not shown). However, we could not observe 
expression differences and also the total expression was similar to that in HEK293 
cells (Fig.5.2). 
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Fig. 5.2. Expression in human placenta: RNA was isolated from placenta tissue, reverse 
transcribed and expression of HBCBP was determined by quantitative real-time PCR using 
specific primers for HBCBP. Values were normalized to the housekeeping gene PBGD. 
HEK293 cells were taken as reference cell line due to comparably low expression value of 
HBCBP. Pool of 12 values. Graph shows means ± SEM.  Statistics calculated using 
Student‘s t-test (n.s. t-test >0.05) 
 
 
 
We thought, that the low expression level of HBCBP in the placenta samples could 
probably refer to the fact that the samples originated from late pregnancies. Another 
commercially available tissue panel (Multi-Tissue cDNA Panel (Clontech)) was 
analyzed in which the placenta sample was supposed to contain a pool of placenta 
cDNA comparable to the RNA-Panel we used before. In this experiment, the 
expression level in placenta did not stand out of the other tissues, finally hinting, that 
the higher expression level in the RNA panel was a false positive (Fig.5.3). 
 
 
 
 
 
 
 
 
 
Fig. 5.3. Human Multi-Tissue cDNA Panel: Expression of HBCBP was determined by 
quantitative real-time PCR using specific primers for HBCBP. Values were normalized to the 
housekeeping gene PBGD. Graph shows relative expression of HBCBP compared to kidney. 
The cDNA panel was composed of one sample per tissue. 
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6. HBCBP Promotor 
 
 
From the previous experiments we did not yet get a hint about cellular processes 
HBCBP could be involved in. Therefore, we wanted to analyze a hypothetical HBCBP 
promoter to see possible transcription factor binding sites that could give a clue in 
which processes HBCBP expression is modified and needed.  
We defined our hypothetical HBCBP promoter reaching -900 to +300 bp from the 
transcription start of HBCBP and analyzed it using the MatInspector software 
(Genomatix, Munich, D), that filters out potential binding sites and calculates their 
probability to be specific by similarities of the core sequence (highest conserved 
sequence) and their surrounding sequences (Optimized Matrix Similarity Threshold). 
A value between 0.80 and 1.00 can be considered as a “good match”. The outcome 
of our analysis was a long list of different possible regulatory sites in this hypothetical 
HBCBP promoter with variable Optimized Matrix Similarity Thresholds. The list 
shown in the figures resembles an excerpt of these binding sites (Fig.6.1). 
 
 
Family/matrix Further Information Opt. From – To Core 
sim. 
Matrix 
sim. 
V$CREB/VJUN.01 V-Jun 0.78 48-68 1.000 0.862 
V$CREB/VJUN.01 V-Jun 0.78 49-69 0.750 0.858 
V$SMAD/SMAD3.01 Smad3 transcription factor involved in 
TGF-beta signaling 
0.99 172-180 1.000 0.993 
V$ETSF/ELK1.01 Elk-1 0.82 192-208 0.800 0.824 
V$SMAD/SMAD3.01 Smad3 transcription factor involved in 
TGF-beta signaling 
0.99 370-378 1.000 0.991 
V$PERO/PPARA.01 PPAR/RXR heterodimers 0.70 391-411 0.807 0.702 
V$AREB/AREB6.01 AREB6 (Atp1a1 regulatory element 
binding factor 6) 
0.97 401-413 1.000 0.990 
V$AREB/AREB6.02 AREB6 /Atp1a1 regulatory element 
binding factor 6) 
0.97 591-603 1.000 0.970 
V$AREB/AREB6.03 AREB6 /Atp1a1 regulatory element 
binding factor 6) 
0.98 737-749 1.000 0.991 
V$E2FF/E2F.01 E2F, involved in cell cycle regulation, 
interacts with Rb p107 protein 
0.84 772-786 0.857 0.843 
 71
V$RXRF/VDR 
RXR.01 
VDR/RXR Vitamin D receptor RXR 
heterodimer site 
0.85 824-840 1.000 0.851 
V$PERO/PPARA.01 PPAR/RXR heterodimers 0.70 826-846 0.807 0.745 
V$RORA/TR4.01 Nuclear hormone receptor TR4 
homodimer binding site 
0.84 834-852 0.750 0.842 
V$ETSF/ELK1.01 Elk-1 0.82 861-877 0.800 0.844 
V$NFKB/CREL.01 C-Rel 0.91 864-878 1.000 0.912 
V$NFKB/NFKAPPAB.
01 
NF-kappaB 0.84 864-878 1.000 0.854 
V$IRFF/IRF2.01 Interferon regulatory factor 2 0.80 902-920 0.750 0.804 
V$RORA/NBRE.01 Monomers of the Nur subfamily of nuclear 
receptors (Nur77, Nurr1, Nor-1) 
0.89 942-960 1.000 0.895 
V$RORA/RORA2.01 RAR-related orphan receptor alpha2 0.82 968-986 1.000 0.877 
V$STAT/STAT3.01 Signal transducer and activator of 
transcription 3 
0.74 1021-1019 1.000 0.743 
V$PERO/PPARA.01 PPAR/RXR heterodimers 0.70 1115-1135 0.807 0.794 
V$NFKB/NFKAPPAB.
02 
NF-kappaB 0.82 1138-1152 0.750 0.825 
V$SP1F/TIEG.01 TGFbeta-inducible early gene 
(TIEG)/early growth response gene alpha 
(EGRalpha) 
0.83 1185-1199 1.000 0.878 
 
Fig. 6.1. Promotor analysis using MatInspector: The genomic sequence that was analyzed 
was reaching -900 to +300 bp from the transcription start of HBCBP (1200 bp). The table 
shows an excerpt of the obtained potential binding sites. Family/Matrix: the V$ indicates 
vertebrate-group, followed by an acronym for the factor the matrix refers to, and a number 
discriminating between different matrices for the same factor. Opt.: Optimized matrix 
similarity threshold: This matrix similarity is the optimized value defined in a way that a 
minimum number of matches are found in non-regulatory test sequences. Core sim.: Core 
similarity: The “core sequence” of a matrix is defined as the (usually 4) highest conserved 
positions of the matrix. The maximum core similarity of 1.0 is only reached when the highest 
conserved bases of a matrix match exactly in the sequence. Matrix similarity: A perfect 
match to the matrix hits a score of 1.00 (each sequence position corresponds to the highest 
conserved nucleotide at that position in the matrix), a “good” match to the matrix usually has 
a similarity of <0.80. Mismatches in highly conserved positions of the matrix decrease the 
matrix similarity more than mismatches in less conserved regions. 
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In order to see, if the predicted TGFβ1 responsible sites in the hypothetical HBCBP 
promoter are active, we stimulated HepG2 cells for the indicated time periods with 
TGFβ1 in a concentration of 50ng/ml. We used HepG2 because, after analysis of 
several cell lines, HepG2 cells showed the highest expression level. The expression 
level of HBCBP showed an increase after stimulation with TGFβ1. Although that 
increase was not significant, there was a clear trend (Fig.6.2.1.). 
 
 
 
 
 
 
 
 
 
Fig. 6.2.1. Analysis of HBCBP expression regulation: Determination of the expression rate of 
HBCBP in HepG2-cells treated with TGFβ1. HepG2 cells were seeded in 6-wells. In the 
subconfluent state, the cells were treated with 50ng/ml TGFβ1 for the indicated time periods, 
RNA was isolated, reverse transcribed and expression of HBCBP was analyzed by 
quantitative real-time PCR using specific primers for HBCBP. These values were normalized 
to the housekeeping gene PBGD. Control values were set to 1. HBCBP expression was not 
significantly influenced by TGFβ1 treatment. Pool of values from 4 independent experiments. 
Graph shows means ± SEM.  Statistics calculated using Student‘s t-test (n.s. t-test >0.05). 
 
 
We decided that experiments related to expression stimulation should be done in a 
primary cell line, not influenced by altered gene expression regulation. So for the 
further experiments we used HUVECs. TGFβ1 stimulation in HUVECs also did not 
significantly alter the expression of HBCBP but also here the trend was clear 
(Fig.6.2.2.). 
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Fig. 6.2.2. Analysis of HBCBP expression regulation: Determination of the expression rate of 
HBCBP in HUVECs treated with TGFβ1. HUVECs were seeded in 6-wells. In the 
subconfluent state, the cells were treated with 50ng/ml TGFβ1 for the indicated time periods, 
RNA was isolated, reverse transcribed and expression of HBCBP was analyzed by 
quantitative real-time PCR using specific primers for HBCBP. These values were normalized 
to the housekeeping gene PBGD. Control values were set to 1. HBCBP expression was not 
significantly influenced by TGFβ1 treatment. Pool of values from 3 independent experiments. 
Graph shows means ± SEM.  Statistics calculated using Student‘s t-test (n.s. t-test >0.05) 
 
 
 
We found a possible Interferon regulatory factor (IRF) responsive site and a possible 
Signal Transducer and Activator of Transcription (STAT) responsive site that is 
known to be regulated by cytokines. Therefore we stimulated HUVECs with the 
cytokines IFNγ, IFNα or TNFα and analyzed the expression of HBCBP in these cells 
in comparison to the housekeeping gene PBGD. HBCBP expression was not 
changed upon stimulation with IFNα or TNFα, but there was a clear trend of 
upregulation upon IFNγ treatment (though not significant) (Fig.6.2.3.). 
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Fig. 6.2.3. Expression analysis of HBCBP in HUVECs treated with different cytokines: 
HUVECs cells were seeded in 6-wells. In the subconfluent state, the cells were treated with 
100ng/ml IFNγ, 100ng/ml IFNα or 100ng/ml TNFα for the indicated time periods. HBCBP 
expression was not significantly influenced by cytokine treatment. Pool of values from 2 
independent experiments. Graph shows means ± SEM.  Statistics calculated using Student‘s 
t-test (n.s. t-test >0.05). 
 
 
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that get 
activated upon binding to their ligands. To check, if the predicted PPAR responsible 
sites in the analyzed HBCBP promoter are active, we stimulated HUVECs with the 
PPARα ligand WY14643 or the PPARγ ligand Rosiglitazone-Maleate. HBCBP 
expression was not significantly altered upon PPAR ligand stimulation indicating that 
these sites are not active (Fig.6.2.4.). 
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Fig. 6.2.4. Expression analysis of HBCBP in HUVECs treated WY14643 or Rosiglitazone-
Maleate: HUVECs cells were seeded in 6-wells. In the subconfluent state, the cells were 
treated with the PPARα ligand Wy14643 (100µM) or PPARγ ligand Rosiglitazone-maleate 
(10µM) for the indicated time periods. HBCBP expression was not significantly altered upon 
PPAR ligand treatment. Pool of values from 2 independent experiments. Control values were 
set to 1. Graph shows means ± SEM.  Statistics calculated using Student‘s t-test (n.s. t-test 
>0.05). 
 
 
 
Elk-1, v-Jun and E2F transcription factor responsible sites in the hypothetical HBCBP 
promoter indicated that the expression of HBCBP could be regulated through MAP-
Kinases. Therefore we used the general MAP-Kinase activator PMA to stimulated 
HUVECs, but the HBCBP expression was not significantly different to that in the 
control cells (Fig.6.2.5.). 
 
 
 
 
 
 
 
 
 
Fig. 6.2.5. Expression analysis of HBCBP in HUVECs-cells treated with PMA: HUVECs cells 
were seeded in 6-wells. In the subconfluent state, the cells were treated with 50nM PMA for 
the indicated time periods. HBCBP expression was not significantly influenced by PMA 
treatment. Pool of values from 2 independent experiments. Graph shows means ± SEM.  
Statistics calculated using Student‘s t-test (n.s. t-test >0.05). 
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NBRE-sites are binding sites for the nuclear receptors Nur77, Nor1 and Nurr1. In 
order to find out, if this site is active, we overexpressed Nur77 in HUVECs and 
analyzed the expression level of HBCBP, but the expression rate was not 
significantly altered, indicating that this predicted site is not active (Fig.6.2.6.). 
 
 
 
 
 
 
 
 
 
Fig. 6.2.6. Expression analysis of HBCBP in HUVECs overexpressing Nur77: HUVECs were 
seeded in 6-wells. In the subconfluent state, the cells were transfected using Lipofectamine 
Plus reagent according to manufacturer’s protocol with full length Nur77 overexpression 
vector pcDNA3.1-Nur77. Nur77 overexpression did not significantly influence the expression 
rate of HBCBP. Graph shows means ± SEM.  Statistics calculated using Student‘s t-test (n.s. 
t-test >0.05). 
 
 
 
AREB6 is known to be upregulated upon Prostaglandin E2 (PGE2) stimulation. We 
analyzed if the predicted AREB6 responsible binding sites are active by treating 
HUVECs with PGE2 and analyzed the expression rate of HBCBP. There was no 
significant change upon PGE2 stimulation, indicating that these sites are not active 
(Fig.6.2.7.). 
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Fig. 6.2.7. Expression analysis of HBCBP in HUVECs treated with Prostaglandin E2: 
HUVECs cells were seeded in 6-wells. In the subconfluent state, the cells were treated with 
10µg/ml PGE2 for the indicated time periods. Treatment with PGE2 did not significantly alter 
the expression rate of HBCBP. Pool of values from 4 independent experiments. Graph 
shows means ± SEM.  Statistics calculated using Student‘s t-test (n.s. t-test >0.05). 
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7. In silico structural analysis of HBCBP protein 
 
 
Next we analyzed the protein structure to see if that could give a clue about the 
function of the protein. For that purpose we analyzed the nucleotide or protein 
sequence of HBCBP in different in-silico programs available.  
 
The ClustalW2 sequence analysis program is a tool to analyze evolutionary 
relationships between proteins. On the ENSEMBL homepage sequences of predicted 
orthologues of human HBCBP in different species were found. These sequences 
were aligned by the ClustalW2 program to get a hint about the evolutionary descent 
(Fig. 7.1.). The sequences aligned in various extend to human HBCBP. Compared to 
human HBCBP, chimpanzee HBCBP aligned to 96%, showing the highest similarity. 
Guinea pig, armadillo and guinea pig HBCBP showed similarities of about 50%. 
Lesser hedgehog tenrec with only 37 aligning basepairs showed the lowest similarity.  
 
 
 
SeqA Name Len(aa) SeqB Name Len(aa) Score 
1 Human 196 2 Chimpanzee 197 96 
1 Human 196 3 Elephant 183 53 
1 Human 196 4 Armadillo 156 54 
1 Human 196 5 Guinea 156 54 
1 Human 196 6 Tenrec 170 32 
2 Chimpanzee 197 3 Elephant 183 50 
2 Chimpanzee 197 4 Armadillo 156 52 
2 Chimpanzee 197 5 Guinea 156 52 
2 Chimpanzee 197 6 Tenrec 170 34 
3 Elephant 183 4 Armadillo 156 57 
3 Elephant 183 5 Guinea 156 57 
3 Elephant 183 6 Tenrec 170 48 
4 Armadillo 156 5 Guinea 156 100 
4 Armadillo 156 6 Tenrec 170 28 
5 Guinea 156 6 Tenrec 170 28 
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Fig. 7.1. ClustalW2 sequence analysis for potential evolutionary decent of human HBCBP 
gene: Amino acid sequences of predicted orthologues of HBCBP from ENSEMBL homepage 
were used for alignment in order to gain information about a possible evolution of human 
HBCBP gene. The list shows the score calculated from the alignment between the 
sequences from 2 indicated species. The Len(aa) value resembles the length of the amino 
acid sequence of the aligned sequence. Among the predicted HBCBP sequences in the 
different species, only the predicted chimpanzee HBCBP sequence seemed to be an 
orthologue of human HBCBP. The result of the alignment is shown in a phylogram. Human 
HBCBP showed a high degree of similarity to chimpanzee HBCBP, indicating a probability of 
being an orthologue, but it only aligned to a low extend to HBCBP sequences found in the 
other species. 
 
 
 
The Block Searcher program is a software to detect sequence homologies between 
different proteins in one species, in order to find related sequences. We used this 
program to find possible related sequences of HBCBP, but only a very short 
sequence of the Eurkaryotic Molybdopterin Domain Signature that aligned partially to 
human HBCBP in a stretch of 13 amino acids was found. This result indicated that 
HBCBP has no related sequences in the entire human genome (Fig. 7.2.). 
 
 
Hits Aligns to AA Combined E-value 
Eukaryotic Molybdopterin Domain Signature 103-116 0.053 
 
Fig. 7.2. Block Searcher analysis: Block Searcher was used to detect protein sequence 
homologies of HBCBP to other proteins and to find possible related sequences. The 
complete 196 amino acid sequence of human HBCBP was analyzed. There was only one 
possible hit, the Eukaryotic Molybdopterin Domain Signature, that aligned to a very short 
fragment of human HBCBP (amino acids 103-116), with a resulting E-value (expect value) of 
0.053 (optimal value is 0). This result indicated that this alignment was not due to a related 
descent. 
human
chimpanzee
armadillo
guinea pig
elephant
tenrec
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The SMART program is used to identify domain structures in proteins. We submitted 
the full length HBCBP sequence, but the software could only detect low complexity 
regions with HBCBP (Fig. 7.3.). 
 
 
Name Begin End E-value 
Low complexity 5 13 - 
Low complexity 48 58 - 
 
Fig. 7.3. SMART analysis: The SMART program was used to analyse the HBCBP amino acid 
sequence to get hints about possible domain structures. The software could only detect low 
complexity regions in the sequence. 
 
 
 
We used the ELM server (Heidelberg, Germany) to analyze the complete 196 amino 
acid sequence of HBCBP for conserved domains. The majority of the potential 
conserved domains are predicted to have a function apart from cytosol although we 
found that HBCBP was exclusively located in the cytoplasm. Among the predicted 
domains that have a function in the cytosol there were several potential 
phosphorylation sites, like casein kinase 1 and 2 (CK1, CK2) phosphorylation sites 
and a potential phosphorylase kinase (PK) phosphorylation site (Fig.7.4.1 and Fig. 
7.4.2.). 
 
 
 
 
 
7.4.1. 
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7.4.2. 
Elm Name Positions Elm Description Cell Compartment 
CLV_NDR_NDR
_1 
106-108 N-Arg dibasic convertade (nardilysine) cleavage site Extracellular, Golgi 
apparatus, cell surface 
LIG_FHA_2 83-89 Phosphothreonine motif binding a subset of FHA domains 
that have a preference for an acidic amino acid at the 
pT+3 position 
Nucleus, replication fork 
LIG_PDZ_3 45-48; 61-64; 72-75; 
111-114; 157-160 
Class III PDZ domain binding motif Cytosol, plasma 
membrane, membrane 
LIG_SH3_3 27-33; 131-137; 168-
174 
Motif recognized by those SH3 domains with a non-
canonical class I recognition specificity 
Cytosol, plasma 
membrane, focal adhesion 
LIG_TRAF2_1 35-38 Major TRAF2-binding consensus motif. Members of the 
tumor necrosis factor receptor (TNFR) superfamily initiate 
intracellular signaling by recruiting the C-domain of the 
TNFR-associated factors (TRAFs) through their 
cytoplasmic tails. 
Cytosol 
LIG_USP7_1 132-136 The USP7 NTD domain binding motiv variant based on 
the MDM3 and P53 interactions 
Nucleus 
MOD_CK1_1 24-30; 50-56; 86-92; 
156-162; 162-168 
CK1 phosphorylation site Nucleus, cytosol,  
MOD_CK2_1 82-88; 182-188 CK2 phosphorylation site Nucleus, cytosol, protein 
kinase CK2 complex 
MOD_CMANNO
S 
9-12 Motif for attachment of a mannosyl residue to a 
tryptophan 
Extracellular 
MOD_GSK3_1 24-31; 82-89; 132-
139; 150-157; 162-
169; 182-189; 186-
193 
GSK3 phosphorylation recognition site Nucleus, cytosol 
MOD_PIKK_1 12-18; 36-42; 62-68; 
64-70; 86-92; 159-165 
(ST)Q motif which is phosphorylated by PIKK family 
members 
nucleus 
MOD_PK_1 190-196 Phosphorylase kinase phosphorylation site Cytosol 
MOD_PKA_1 107-113; 190-196 PKA is a protein kinase involved in cell signaling Cytosol; cAMP-dependent 
protein kinase complex 
MOD_ProDKin_1 28-34;47-53;95-
101;100-106;130-136 
Proline-Directed Kinase (e.g. MAPK) phosphorylation site 
in higher eukaryotes.  
Nucleus, cytosol 
 
 
Fig. 7.4. ELM-EMBL analysis of HBCBP amino acid sequence: The complete 196 AA 
sequence of HBCBP was submitted to the ELM server, to analyze the sequence for potential 
conserved domain patterns. The graph and list shows the obtained result. Considering 
HBCBP to be a cytoplasmic protein excludes some of the listed matched, leaving mostly 
potential phosphorylation sites. 
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The PredPhospho program finds possible phosphorylation sites within sequences by 
comparing to known phosphorylation site patterns. The program could detect a 
variety of different possible serine and threonine phosphorylation sites in the full 
length amino acid sequence of HBCBP (Fig. 7.5.1.).  
 
 
 
 
 
 
 
 
Fig. 7.5.1.. The PredPhospho software and NetPhos 2.0 server: Analysis of full length amino 
acid sequence of HBCBP. Using this program a list of potential serine and threonine 
phosphorylation sites was obtained and their assumed locations. 
 
 
 
The NetPhos 2.0 Server is another possibility to analyze a sequence for predicted 
phosphorylation sites. Using this program to analyze the full length amino acid 
sequence of HBCBP we also got a list of predicted phosphorylation sites, mostly 
serine and threonine sites (Fig. 7.5.2). These sites only matched to a low extend the 
result we got from the PredPhospho program.  
 
 
7.5.2.a. 
 
 
 
 
 
 
 
 
 
Query MISEGGWGWQ GWGRSQGLRP APCSWVSRMV SPPAAIQETQ LHFLADTLPS PLSILLPPHK 60
Phospho_site P P P P P P 60
Query QEELSQSQLL IADLLPASDL GNFQTSRETQ SYQKAQPTPI SFSPDHRKVS RDVIPGAALG 120
Phospho_site P P P 120
Query TASSRCWQML CPSPSVPGTR WGRPQWKLLN SVTGQSSDTV ISQFSLAMSF PNFPVPQLRF 180
Phospho_site P P P P P 180
Query LNTCSTDETK KSSVNK 196
Phospho_site P P PP 196
 
196 gi_33328310  
MISEGGWGWQGWGRSQGLRPAPCSWVSRMVSPPAAIQETQLHFLADTLPSPLSILLPPHKQEELSQSQLLIADLLPASDL      80 
GNFQTSRETQSYQKAQPTPISFSPDHRKVSRDVIPGAALGTASSRCWQMLCPSPSVPGTRWGRPQWKLLNSVTGQSSDTV     160 
ISQFSLAMSFPNFPVPQLRFLNTCSTDETKKSSVNK                                                 240 
..............................S.................................S...............      80 
....TS...........T....S......S..................................................     160 
........................S...T..S....                                                 240 
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7.5.2.b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7.5.2. NetPhos 2.0 Server (Technical University of Denmark, Lyngby, Denmark): 
Analysis of full length amino acid sequence of HBCBP. Using this program a list of possible 
serine and threonine phosphorylation sites and a single tyrosine phosphorylation site was 
obtained. The result only partially matched the result of the PredPhospho software.  
 
 
To analyze HBCBP for phosphorylation we used anti-phospho-Ser antibody or anti-
phospho-Thr antibody on cell lysates containing overexpressed Myc-HBCBP and 
truncated Myc-tagged constructs, but we could neither detect a signal for P-Ser nor 
P-Thr (data not shown). 
 
 
 
 
 
 
 
 
Phosphorylation sites predicted: Ser: 7 Thr: 3 Tyr: 0
Serine predictions
Name           Pos   Context    Score  Pred
_________________________v_________________
gi_33328310      3   --MISEGGW  0.003    .
gi_33328310     15   GWGRSQGLR  0.005    .
gi_33328310     24   PAPCSWVSR  0.064    .
gi_33328310     27   CSWVSRMVS  0.045    .
gi_33328310     31   SRMVSPPAA  0.959  *S*
gi_33328310     50   DTLPSPLSI  0.175    .
gi_33328310     53   PSPLSILLP  0.021    .
gi_33328310     65   QEELSQSQL  0.915  *S*
gi_33328310     67   ELSQSQLLI  0.010    .
gi_33328310     78   LLPASDLGN  0.157    .
gi_33328310     86   NFQTSRETQ  0.984  *S*
gi_33328310     91   RETQSYQKA  0.116    .
gi_33328310    101   PTPISFSPD  0.039    .
gi_33328310    103   PISFSPDHR  0.873  *S*
gi_33328310    110   HRKVSRDVI  0.975  *S*
gi_33328310    123   LGTASSRCW  0.103    .
gi_33328310    124   GTASSRCWQ  0.104    .
gi_33328310    133   MLCPSPSVP  0.049    .
gi_33328310    135   CPSPSVPGT  0.353    .
gi_33328310    151   KLLNSVTGQ  0.070    .
gi_33328310    156   VTGQSSDTV  0.011    .
gi_33328310    157   TGQSSDTVI  0.120    .
gi_33328310    162   DTVISQFSL  0.085    .
gi_33328310    165   ISQFSLAMS  0.097    .
gi_33328310    169   SLAMSFPNF  0.402    .
gi_33328310    185   LNTCSTDET  0.612  *S*
gi_33328310    192   ETKKSSVNK  0.671  *S*
gi_33328310    193   TKKSSVNK- 0.413    .
_________________________^_________________
Threonine predictions
Name           Pos   Context    Score  Pred
_________________________v_________________
gi_33328310     39   AIQETQLHF  0.034    .
gi_33328310     47   FLADTLPSP  0.106    .
gi_33328310     85   GNFQTSRET  0.992  *T*
gi_33328310     89   TSRETQSYQ  0.075    .
gi_33328310     98   KAQPTPISF  0.585  *T*
gi_33328310    121   AALGTASSR  0.041    .
gi_33328310    139   SVPGTRWGR  0.096    .
gi_33328310    153   LNSVTGQSS  0.006    .
gi_33328310    159   QSSDTVISQ  0.030    .
gi_33328310    183   RFLNTCSTD  0.072    .
gi_33328310    186   NTCSTDETK  0.026    .
gi_33328310    189   STDETKKSS  0.892  *T*
_________________________^_________________
Tyrosine predictions
Name           Pos   Context    Score  Pred
_________________________v_________________
gi_33328310     92   ETQSYQKAQ  0.499    .
_________________________^_________________
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8. Recombinant HBCBP 
 
 
For most the previous experiments the overexpression of HBCBP was used as a tool 
for analyses. To analyze the endogenous protein we expressed and purified the 
recombinant HBCBP protein in order to use it as an antigen to produce antibodies. 
For this, the full-length HBCBP sequence was cloned into the bacterial expression 
vector pET24a creating a fusion construct with His-tag that was expressed in 
bacteria. After lysis, the cell debris containing the inclusion bodies was separated 
from the cell lysate by centrifugation and both lysates and inclusion bodies were 
analyzed using Western blot. An anti-His antibody (Sigma, St. Louis, MO) showed 
that recombinant HBCBP exclusively was present in the inclusion bodies and was not 
detectable in the cell lysate. Isolation of recombinant protein from inclusion bodies 
includes the denaturation of the protein and subsequent renaturation with a high risk 
of misfolding and so we did not preceed (Fig. 8). 
 
 
 
 
 
 
 
 
 
Fig. 8. Expression of recombinant His-tagged HBCBP was induced using IPTG in bacteria. 
Cell lysates and cell debris containing inclusion bodies were subjected to Western blot. 
Membranes were developed using an anti-His antibody (Sigma, St. Louis, MO). 
Recombinant HBCBP was not detectable in the cell lysate, it was exclusively present in the 
cell debris containing the inclusion bodies. A representative of two independent experiments 
is shown. 
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DISCUSSION 
 
 
DEP-1, by influencing MAP-Kinase pathways, plays an important role in the 
regulation of cell growth and differentiation. The antiproliferative feature of DEP-1 and 
the fact, that the gene is often lost in different kinds of human cancers are the reason 
for its designation as a tumor suppressor gene. In addition, DEP-1 plays a 
fundamental role in the development of the vascular system during embryogenesis.  
 
In order to find out more about the function of DEP-1, we were searching for new 
interaction partners, to get a better idea about its place in the diffuse network of 
signal transduction pathways. A very useful tool for this purpose is the Matchmaker 
Y2H system as described previously (Maple and Moller, 2007), an in-vivo-system to 
identify interaction partners of the gene-of interest. My diploma thesis took advantage 
of the Y2H-system and reported about the confirmed interaction between DEP-1 and 
a newly identified protein, Hepatitis B core-Antigen Binding Protein (HBCBP).  
 
There was no information available about structure, regulation of function of this new 
gene and protein. The nucleotide sequence of HBCBP was published in 2003 on 
NCBI (Bethesda, MD) and was initially identified as an interaction partner of Hepatitis 
B Core Antigen (HBcAG) in an Y2H screen (Lu et al, 2005). Apart from this 
publication, there was no scientific data available that described HBCBP. Hence we 
were interested, how the interaction with DEP-1 influences cellular processes.  
 
A very important function of DEP-1 is the inhibition of MAP-Kinase activity. In this 
context, we were interested, if HBCBP may also influence these pathways. To study 
this aspect, we used the PathDetect Elk-1 reporter system as a read-out for ERK1/2 
activity which was also previously used by Iwata et al (Iwata et al, 2001), and we 
found, that overexpression of HBCBP as well as of DEP-1 downregulated the activity 
of Elk-1 and in case of overexpression of both proteins this inhibition is even more 
pronounced. The specificity of this effect was proven by the use of PMA, a general 
MAP-Kinase activator (Harvey et al, 2008; Lang et al, 2004), the titration of pCMV-
Myc-HBCBP to see a dose-dependent inhibition and the use of truncated HBCBP 
constructs that did not affect the activity of Elk-1. 
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DEP-1 protein is upregulated in cells when they reach confluency (Ostman et al, 
1994), and this stops cell growth. To this aspect, we were interested, if HBCBP 
activity could also be influenced by cell density. Surprisingly we found out, that 
HBCBP did not inhibit Elk-1 activity in the sparsely grown cells, that it had a limited 
effect in the subconfluent cells, and that it had the most pronounced effect in the 
confluently grown cells indicating that the activity of HBCBP is dependent of the cell 
density.  
 
In this context we were interested if HBCBP expression is also dependent by cell 
density, what could have been crucial for further experiments. We used in increasing 
stages of confluence and analyzed HBCBP expression with Q-PCR according to the 
analysis model of Pfaffl (Pfaffl et al, 2001), but we could not detect a modified 
expression regulation of the protein.  
 
Similarly we were interested if the expression could be modified by cell malignacy 
and compared HBCBP expression of LNCaP cells, a prostate epithelial cancer cell 
line with that of RWPE1, a normal prostate epithelial cell line, but also here we could 
not detect significant differences, indicating that HBCBP expression is not depending 
on cell malignacy.  
 
We reported previously about the interaction of HBCBP and DEP-1 in the yeast 
system. We also wanted to confirm this interaction in the human system. For this 
purpose we wanted to do CoIP. When we used an anti-Myc antibody for pull-down, 
overexpressed Myc-HBCBP was precipitated, but it did not coprecipitate DEP-1 
(neither endogenous nor overexpressed HA-DEP-1). For the next step we reduced 
the stringency by reducing the salt concentration to 150mM (resembles PBS NaCl 
concentration). But still, DEP-1 did not coprecipitate with HBCBP.  
We considered that the Myc-epitope in the folded Myc-HBCBP protein might have 
been in close proximity to the possible DEP-1 binding domain and that could have 
prevented their interaction. We tried to do the approach vice versa and used an anti-
DEP-1 antibody for the pull down, to precipitate DEP-1 (endogenous and 
overexpressed) and to coprecipitate Myc-HBCBP. Also in this case, the precipitation 
of DEP-1 could be detected, but HBCBP was not pulled down with its suspected 
interaction partner, neither in higher nor less stringent salt concentrations. 
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For the further CoIPs we used Dynabeads, because their surface can be more 
efficiently saturated with antibodies, and therefore they should yield a higher amount 
of pull down. Dynabeads have to be covalently linked to the desired antibody prior to 
use, promising a better probability of detection of interacting proteins, as described 
by Froystad (Froystad et al, 1998). As a control, we used Dynabeads linked to normal 
mouse IgG. As desired DEP-1 was precipitated only with Dynabeads linked to anti-
DEP-1 antibody and Myc-HBCBP was found to be coprecipitated in this set of 
samples (with endogenous as well as overexpressed DEP-1), but unfortunately 
similar bands were found in the set, in which normal IgG were used for the control IP. 
This indicated that Myc-HBCBP did not specifically coprecipitate with DEP-1, but 
bound either to the control IgG or to the Dynabeads themselves.  
After we figured out, that Dynabeads are probably not the right approach to do 
CoIPs, we finally also tried to see the interaction by a “modified ELISA experiment”. 
Microtiter plates were coated with polyclonal anti-DEP-1 antibody (rabbit) or rabbit 
immunoglobulin fraction as a control. Also in this approach Myc-HBCBP not only 
bound to the wells coated with rabbit anti-DEP-1 antibody, but also bound to the 
wells coated with rabbit immunoglobulin fraction and even to uncoated wells. So Myc-
HBCBP could not be detected due to the interaction with DEP-1 but because of 
unspecific binding. 
The results of all trials of CoIPs let us guess, that Myc-HBCBP could possibly bind 
unspecifically to plastic surfaces as shown with microtiter plates, and probably a 
similarly unspecific binding resulted in the CoIP result when using Dynabeads. If we 
hypothesize, that HBCBP possibly is a hydrophobic protein, it would generally bind in 
an unspecific way to a wide variety of surfaced, not only proteins. But after all, even 
in the lowest possible stringency, Myc-HBCBP did not interact with DEP-1 in a 
detectable way. If there was an interaction of Myc-HBCBP and DEP-1 the Myc-
HBCBP band should have been stronger in samples with overexpressed HA-DEP-1 
and the Myc-HBCBP band should have been literally absent or at least less strong 
pronounced in the control CoIP using normal IgG or rabbit immunoglobulin fraction 
compared to the CoIP using anti-DEP-1 antibodies.  
When stating the theory, that HBCBP was a hydrophobic protein we also had to 
consider the possibility of a false positive result in the Y2H-system shown in my 
diploma thesis demonstrating the interaction between HBCBP and DEP-1. Unspecific 
binding due to hydrophobic interactions could bring the bait and prey fusion proteins 
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in close enough proximity to start transcription of the reporter genes and the yeast 
colonies could grow. 
 
Now we wanted to see, in which compartment of the cell HBCBP was localized. Due 
to the fact, that we could not prove the interaction of HBCBP and DEP-1 in the 
mammalian system, we wanted to know, if an interaction is generally possible. For 
that purpose we studied the co-localization by confocal microscopy (Papac-Milecevic 
et al, 2009, in revision). EGFP-tagged HBCBP was overexpressed together with HA-
tagged wild type DEP-1 or ∆cyto-DEP-1 and the samples were stained with anti-
DEP-1 antibody (epitope at extracellular domain of DEP-1) and a second anti mouse 
Alexa 568 antibody. These experiments showed us, that HBCBP was exclusively 
localized in the cytoplasm of the cells, meaning that a physical contact with DEP-1 
was possible. There were also indications of a colocalization of HBCBP and wild type 
DEP-1 in proximity of the cell membrane, hinting to a possibility of interaction, but a 
similar picture could be seen, when HBCBP was coexpressed with ∆cyto-DEP-1. 
∆cyto-DEP-1 lacks the entire intracellular domain of the protein, so a direct 
interaction of HBCBP with this protein was not possible. Although there was now 
difference visible between the image of HBCBP and full-length or mutant DEP-1, it is 
possible, that there was an interaction between HBCBP and DEP-1, although too 
weak to be detectable or that the interaction only occurs under determined 
circumstances.  
 
After we saw, that there was no interaction between HBCBP and DEP-1 that was 
strong enough to be detectable, we wanted to see, if the inhibitory effect of HBCBP 
on the ERK1/2 MAP-Kinase pathway depended on the presence of its previously 
suspected interaction partner, what would hint toward an active interaction between 
these two proteins. Elk-1 reporter assay in combination with siRNA to knock down 
HBCBP or DEP-1 showed that the inhibitory effect of both proteins on this system 
was independent, because in case of silenced DEP-1 HBCBP still downregulated 
Elk-1 activity and also vice versa, in case of silenced HBCBP, DEP-1 still 
downregulated Elk-1 activity. Hence both proteins inhibit the ERK1/2 pathway 
independently. If HBCBP and DEP-1 did interact, and we were just not able to prove 
it, then this interaction was not involved in the inhibition of Elk-1. 
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To confirm the inhibitory effect of HBCBP on the ERK1/2 MAP-Kinase pathway, we 
chose a more direct approach by analyzing the phosphorylation state of ERK1/2 after 
HBCBP overexpression. We found phospho-ERK1/2 to be downregulated after 
HBCBP overexpression, though the decrease was not statistically significant.  
The next question was how HBCBP exerts its inhibitory effect, if not by the interaction 
with DEP-1. Since HBCBP was found to be localized exclusively in the cytoplasm, 
the inhibiting effect on Elk1 could not be mediated directly. In addition, the finding 
that the phosphorylation state of ERK1/2 was reduced after HBCBP overexpression 
suggests an influence that occurs upstream of Elk1. Our first theory was that it could 
interact with other components of the MAP-Kinase pathway, but neither MEK1 nor 
ERK1/2 seemed to interact with Myc-HBCBP. 
Another possibility we considered was, that HBCBP interacted with MAP-Kinase 
Phosphatases (MKPs) that are known to inhibit the MAP-Kinase pathway. DUSP6 
(MKP-3) (Arkell et al, 2007) and DUSP9 (MKP-4) (Muda et al, 1997) are MAP-Kinase 
phosphatases that are located in cytoplasm and that are known to inhibit the ERK1/2 
pathway (Keyse, 2008). But CoIPs using anti-DUSP6 and anti-DUSP9 showed that 
there was no interaction between HBCBP and these two proteins. 
 
Eventually we wanted to see, if HBCBP is generally involved in the regulation of 
proliferation or apotosis at all, mechanisms in which the ERK1/2 MAP-Kinase 
pathway is involved. We did proliferation assays using the BrdU Flow Cytometry 
Assay Kit as previously demonstrated (Schittek et al, 1991), which uses the 
thymidine-analogue BrdU that gets integrated in replicating DNA and that can be 
detected by an antibody. The more cells are proliferating, the more BrdU gets 
integrated. A second approach for studying proliferation was staining of Ki67, which 
is a protein that is only expressed in proliferating cells, but not resting cells (Gerdes 
et al, 1983). After silencing of HBCBP we expected a higher proliferation rate of the 
cells, but we could not detect differences to control cells. For these experiments we 
used HepG2 cells, because, compared to other cell lines, this cell type showed the 
highest expression rate of HBCBP. An additional reason was that we saw in the 
multi-tissue panel that is shown later, that liver, among the other tissues, showed a 
comparably high expression of HBCBP.  
If HBCBP did not alter proliferation, it could still influence apotosis. For that purpose 
we applied AnnexinV staining and PI staining. The ApoAlert® Annexin V-FITC 
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Apoptosis Kit, previousy demonstrated by Gogal (Gogal et al, 2000) uses prelabeled 
Annexin V that binds to phosphatidyl-serine, a fatty acid that gets exposed to the cell 
surface in the process of apoptosis. PI is an intercalating agent that is not supposed 
to pass intact cell membranes. Only in case of membrane damage, as in apoptosis 
and necrosis processes, the substance enters the cell and intercalates with DNA 
(Cunningham et al, 2008). We considered that HBCBP could possibly have a 
suppressing effect on apoptosis, so for this case we expected a higher AnnexinV and 
PI staining after silencing of HBCBP. But in both setups of experiments, the silencing 
of HBCBP did not show an effect.  
To confirm the silencing of HBCBP we did Q-PCR using specific primers for HBCBP. 
Scrambled RNA is used as negative control for siRNA experiments and 
demonstrates that silencing of the gene of interest is due to specificity of siRNA and 
is not due to unspecific effects. In this context it is a common phenomenon that 
scrambled RNA itself shows an increasing effect on the expression rate compared to 
control without transfected RNA. Only in one of the shown graphs, the AnnexinV 
knock down control (Fig. 4.3.2.), we did not see this effect. This indicates a difference 
in transfection efficiency in this set of experiments compared to the other graphs 
related to proliferation and apoptosis, and could therefore be considered as less 
substantial. 
But still, there were no detectable effects of HBCBP on proliferation of apoptosis, 
although we found HBCBP as an inhibitor of the ERK1/2 MAP-Kinase pathway in Elk-
1 reporter assays. These results could be due to the possibility that the effect 
depends on defined circumstances in the cell or that HBCBP affects ERK1/2 
dependent processes other that proliferation or apoptosis like cytoskeleton 
organization, cell adhesion or differentiation.  
 
Now we were searching for hints, in which topics HBCBP could be involved in and 
decided, to check the expression level of HBCBP in different human tissues. We 
hoped that an increased expression level of HBCBP in certain tissues could give us a 
clue on its function. We screened different tissues by the use of a Human Multi-
Tissue RNA Panel that was also used by Zinda (Zinda et al, 2001) and normalized 
the HBCBP value to the value for the housekeeping gene PBGD. We found out, that 
HBCBP was generally expressed in low levels, but we found a markedly increased 
level in placenta tissue. Due to the fact, that the RNA panel was only composed by 
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one sample per tissue type, we now decided to collect more placenta samples to 
confirm the high expression rate of HBCBP in this tissue type. We got a number of 
placenta tissue samples from Semmelweis Frauenklinik, from each placenta one 
sample from the maternal and the fetal part. The samples derived from placentas 
ranging from pregnancy week 36 to 42. After analyzing all samples we could see that 
there was no obvious difference in the expression rate of HBCBP between the 
maternal and fetal samples and there was also no gradual change from the earlier 
weeks to the later weeks (data not shown). In addition to that, all the collected 
samples showed a low expression rate of HBCBP that was not comparable to the 
high level in the placenta sample of the RNA panel. So we could pool the values from 
these samples and compared it to a cell type that had a similarly low expression level 
HBCBP, HEK293. The placenta sample of the RNA panel was supposed to be a pool 
of samples from different stages of pregnancy. Our collected samples were only from 
late pregnancy. We purchased another set of samples that included placenta, to 
exclude the possibility that the divergence was due to the difference in the state of 
pregnancy. We analyzed the HBCBP expression in the Human Multi-Tissue cDNA 
panel, which was also used for expression analysis by Yang (Yang, et al 2004) and 
could see that the placenta sample in this set did not show an increased expression 
of the protein compared to the other samples. The only conclusion, we could get out 
of these experiments, was that the result from the RNA panel had to be a false 
positive. Perhaps this sample was somehow contaminated, or HBCBP expression 
was somehow upregulated in this sample by an unknown factor, possibly an infection 
or mutation. Taken together, the tissue screen did not give us a helpful hint, in which 
tissues or functions HBCBP could play a role in. 
The expression rate of HBCBP was generally low in all types of tissues and cells that 
we examined. The crossing points we got from the Q-PCR experiments did not vary 
too much between all different tissue types. The differences that can be observed in 
the graphs partially derive from different levels of the housekeeping gene PBGD in 
the various tissues and cell types, althought we could detect slightly higher 
expression levels of HBCBP in liver and the liver cell line HepG2 (data not shown). 
 
Next we analyzed a hypothetic HBCBP promoter to find potential transcription factor 
binding sites. We hoped, that the presence of certain binding sites would give us a 
hint, how the transcription of the protein is regulated and furthermore, in which 
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processes it plays a role and used the MatInspector software to search for potential 
transcription factor binding sites likewise it was previously used to analyze PCAN1 
promotor (Liu at al, 2008). The list shown in the figures is an excerpt of the long list of 
potential active sites we achieved and in the following experiments we tested, if these 
sites were active. 
We started these experiments in HepG2s, but continued stimulation experiments in 
primary cells, because they had altered cell signalling or gene regulation patterns 
(human umbilical vein endothelial cells, HUVECs). 
Neither the PPARα ligand WY14643 nor the PPARγ ligand Rosiglitazone-Maleate 
that should activate PPAR responsible sites (Papac-Milecevic et al, 2009, in revision) 
affected the expression rate of HBCBP. Similarly the general MAP-Kinase activator 
PMA (Harvey et al, 2008, Lang et al, 2004) that was used to check the activity of Elk-
1, v-Jun and E2F sites did change the transcription rate. AREB6 (ZEB1) is supposed 
to be upregulated by PGE2 and thus induce AREB6-responsible sites (Dohadwala et 
al, 2006), but PGE2 treatment did not alter the expression level of HBCBP. Also 
overexpression of Nur77, which should upregulate the transcriptional activity of the 
NBRE-site (Papac-Milecevic et al, 2009, in revision), did not result in significant 
differences in the HBCBP expression. 
Other sites in the list were predicted to be interferon responsive and Signal 
Transducer and Activator of Transcription (STAT) responsive, which are both 
regulated by cytokines (He, 2006). To investigate if these sites were active we used 
the cytokines IFNγ, IFNα and TNFα. IFNα und TNFα did not influence the expression 
rate of HBCBP, but we found a trend of upregulation of HBCBP expression after 3.5 
hrs of treatment with IFNγ, though not to a significant extend.  
Likewise, TGFβ1 treatment slightly upregulated the expression of HBCBP, but it was 
not statistically significant.  
TGFβ signalling plays an important role in a wide variety of different processes like 
embryonic development, adult tissue homeostasis, differentiation and cancer 
progression (Romano, 2009). IFNγ is an important regulator of immunological events 
(Schroder et al, 2004). After seeing a trend of upregulation of HBCBP expression by 
TGFβ1 and IFNγ, we could hypothesize a possible role of HBCBP in these 
processes. 
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We continued to collect in silico data about HBCBP in order to get information about 
the protein hoping to get hints to possible functions.  
An interesting tool is the ClustalW2 sequence analysis program that is used to 
examine evolutionary relationships between proteins by comparison of their amino 
acid sequences (Larkin et al, 2007). We aligned predicted orthologues of human 
HBCBP from five other species that were available on ENSEMBL homepage. 
Compared to human HBCBP these sequences aligned to various extend. The 
predicted HBCBP gene in chimpanzee exhibited 96% similarity to the human version, 
which very likely seems to be an orthologue. The predicted proteins of guinea pig, 
armadillo and elephant had an amino acid sequence with an approximate identity of 
50% to human HBCBP. In contrast, in the lesser hedgehog tenrec, a mammal living 
in Madagaskar and parts of Africa, only a very short sequence (37 basepairs) aligns 
to human HBCBP. This small percentage makes it unlikely to be an expressed 
relative to human HBCBP.  Except for the chimpanzee sequence, the low percentage 
of alignment of the other sequences to the human sequence, rather hinted to a low 
probability of an evolutionary derivation. We considered it to be more likely to be an 
incidentally occurred similarity.  
 
Now we were interested, if there were related sequences to HBCBP in the human 
genome. Therefore we submitted the full length amino acid sequence of HBCBP to 
the Block Searcher program that aligns sequences to the Blocks Database (Henikoff 
et al, 2000). The only result we got from this analysis was a very short alignment of a 
13 amino acid stretch with the Eukaryotic Molybdopterin Domain Signature. The short 
stretch of alignment was obviously an incidental similarity because it was to short for 
a real homology, what is also indicated by the relatively high combined e-value of 
0.053, what resembles a low probability of significance. 
The SMART program, another program used to identify domain structures in proteins 
(Letunic et al, 2006), could only detect low complexity regions within the full-length 
HBCBP amino acid sequence. 
But taking a closer look at the published cDNA sequence of HBCBP on NCBI and 
comparing it to the genomic sequence of chromosome 12, we found, that the gene 
did not contain introns. Over time genes tend to obtain introns by different 
mechanisms (Fedorova and Fedorov, 2003), so the HBCBP-gene was probably 
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introduced to the human genome comparatively recently in evolution and the lack of 
homologous sequences leaves the question, where the gene originated from. 
 
The ELM server is a tool to analyze amino acid sequences of proteins for conserved 
domain patterns (Puntervoll et al, 2003). Due to the knowledge that HBCBP is 
located in cytoplasm, we could exclude the predicted domains which execute 
functions apart from cytoplasm. The remaining predicted domains were mostly 
related to phosphorylation, which tempted us to analyze the sequence for 
phosphorylation sites.  
The PredPhospho program (Que et al, 2009) for prediction of possible 
phosphorylation sites found a variety of different possible serine and threonine 
phosphorylation sites. In parallel we did a similar analysis using the NetPhos 2.0 
Server (Blom et al, 1999), though the results of this analysis matched only to a low 
extend to that of the PredPhospho program.  
But still we were interested if any of these predicted site were really phosphorylated, 
and whether this phosphorylation could modify the activity of HBCBP. We tried to 
detect phosphorylated serine (P-Ser) or threonine (P-Thr) in overexpressed Myc-
HBCBP or the truncated versions, because the prediction almost exclusively 
predicted serine and threonine sites to be phosphorylated, but no tyrosines. This 
analysis indicated that the proteins were not phosphorylated. Nevertheless the 
possibility remains that it requires some trigger to get phosphorylated, or that the 
phosphorylation was below detection limits.  
 
In most of the experiments discussed before we had to use the artificial system of 
transfection of Myc-tagged HBCBP, because there was no antibody available to 
detect endogenous HBCBP. We thought that the possibility to work with the 
endogenously expressed protein would probably help in our research and planned to 
purify recombinant protein to further use it as an antigen for antibody production. Full 
length HBCBP was cloned into pET24a plasmid that was already previously used for 
expression and purification of proteins (Gilsdorf et al, 2006).  
We started to setup the purification procedure, but we could only see that the entire 
amount of protein expressed by the bacteria remained bound to the inclusion bodies 
that were part of the cell debris. There are some attempts that would make it possible 
to isolate proteins out of inclusion bodies, but these procedures include the 
 95
denaturation of proteins that are followed by trials of renaturation. These processes 
lead to a high probability of missfolding and therefore to exposure of epitopes that 
should not be on the surface in the wild type protein. We did not try to generate 
antibodies using peptides, because there is no data available about the 3D-structure 
of the protein and hence, the amino acid stretches that could be exposed as 
epitopes.  
 
Although we found HBCBP to be an inhibitor of ERK1/2 related processes by Elk-1 
reporter assays and by the trend of downregulation of ERK1/2 in western blot after 
HBCBP- overexpression, we could not define this function in more detail. Apart of the 
possible role of HBCBP in some ERK1/2 related process our research did not reveal 
a defined function of HBCBP. Although all relevant controls were done to show the 
specificity of the Elk-1 reporter assays that showed the inhibitory activity of HBCBP 
on the system, we could still hypothesize, that this inhibition was due to some artefact 
of overexpressing the gene. A possible consideration could be that HBCBP, as a 
hydrophobic protein, could unspecifically bind to other proteins in the cell, leading to 
cluster formation, what could be a reason for the demonstrated inhibition.  
For some time, we even considered that the gene could be some kind of pseudogene 
that was actually not actively expressed at all, and that the expression level found in 
the cells resembled some promoter leakage, that the gene was just in the process to 
develop to a gene, or that it was on its way to be eliminated from the genome. But it 
is as well possible, that we just could not find the test conditions needed to study the 
protein in its most active form. 
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